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Abstract 
Background: Hemorrhagic shock is the number one cause of preventable 
deaths after trauma. Hibernation exemplifies a physiological state in which blood 
flow is reduced to a magnitude comparable to that of hemorrhagic shock. However, 
hibernators are naturally shielded from the insults that a similar reduction in blood 
flow would cause in a non-hibernating mammal. Our laboratory previously 
published a small volume resuscitation fluid based on hibernation physiology: 
BHB/M. It has three main components: 1) 4 M BHB, 2) 43 mM melatonin, and 3) 
20% DMSO. Only the indicated concentration of each component of BHB/M has 
been previously tested. For that reason, worked towards the optimization of the 
composition and delivery of BHB/M in order to enhance survival in a rat model of 
hemorrhagic shock. 
Methods and Results: Previously, BHB/M was given as a 1 ml/kg bolus 
followed by a 100 µl/hr slow infusion. BHB/M was administered as either a single 
bolus or a bolus plus slow infusion in acutely operated rats. There were no statistical 
differences (p>0.05) in mean survival times when comparing the bolus only (mean 
survival 496.67 ± 314.59 min. n=6) to the bolus plus slow infusion (mean survival 
149.20 ±142.71 min. n=5) protocol. 
Two separate dose-ranging studies were conducted for both BHB and 
Melatonin. In the BHB dose-ranging study, BHB was administered at either a 4 M, 
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2 M, or 0.4 M concentration in conjunction with 4.3 mM melatonin and 10% 
DMSO. 10-day mean survival showed a dose-dependent trend where the higher the 
concentration of BHB infused the longer the rats survived (4 M BHB, 7.38 ± 1.75 
days; 2 M BHB, 5.25 ± 2.22 days; 0.4 M BHB, 2.07 ± 2.05 days). In the melatonin 
dose-ranging study, melatonin was administered at either a 4.3 mM, 0.43 mM 
0.0043 mM, 0.000043 mM, or 0 mM concentration in conjunction with 4 M BHB 
and 2% DMSO. An osmolarity control composed of 4 M NaCl and 0.000043 mM 
melatonin in 2 % DMSO was also included. Administering 4 M BHB without 
melatonin resulted in very low mean survival times (4.38 ± 1.42 days); the same 
was true when infusing 0.000043 mM  melatonin with 4 M NaCl (4.58 ± 1.42). All 
treatments containing both 4 M BHB and melatonin, regardless of concentration, 
resulted in mean survival times of ~7.5 days. 
A large-volume experiment was conducted in order to compare isotonic 
BHB/M to the standard of care (LR). Rats subjected to 60% blood loss were infused 
with either LR, LR plus 4.3 mM melatonin, 140 mM BHB with 1.5x10-6 mM Mel, 
or 140 mM BHB with 4.3 mM Mel. LR and LR plus 4.3 mM melatonin had 
statistically higher (p<0.05) mean survival times (7.35 ± 1.59 days and 6.73 ± 1.57 
days, respectively) than 140 mM BHB with 1.5x10-6 mM Mel (2.08 ± 1.18 days). 
Conclusions: BHB/M can be administered as a single 1 ml/kg bolus; 
following the bolus with a 100 µl/hr slow infusion is not necessary to obtain a 
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maximum survival benefit. BHB must be administered at a 4 M concentration as 
there is a dose-dependent trend in which the lower the concentration of BHB 
administered the lower the percent survival to 10 days. Melatonin provides 
therapeutic effects at very low concentrations evident by the survival observed 
when administering a solution containing melatonin at a concentration a million-
fold lower than previously published. Furthermore, melatonin is essential for 
survival since 4 M BHB without melatonin had a considerably reduced survival 
rate. A large volume dilute BHB/M is not a viable alternative to the standard of 
care. 
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CHAPTER I: INTRODUCTION 
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Hibernation is an extended period of dormancy to avoid adverse winter 
(cold weather) conditions. Estivation is its summer (warm weather) counterpart. 
During hibernation and estivation, an animal is said to be torpid when dormant 
(Geiser and Mzilikazi 2011). Classic hibernation patterns include bouts of multiple 
days of reduced body temperature with scattered periods of transient normothermia. 
Normothermic events, known as interbout arousals (IBA), interrupt torpidity as the 
animals are briefly aroused from dormancy for periods of approximately 12 to 24 
hours (Roots 2006); Geiser and Mzilikazi (2011). Hibernating animals pose an 
interesting model for human afflictions since during dormancy they encounter 
physiological challenges which would result in disease in a non-hibernating 
species, such as humans, without exhibiting adverse health repercussions (Roots 
2006; Saey 2012). Though an animal cannot become torpid unless genetically 
programmed (Andrews 2007; Melvin and Andrews 2009), the pathways that 
regulate organ function are common to all mammals. It is through the modification 
of these pathways that hibernators overcome extreme physiological conditions 
(Carey, Martin et al. 2012). 
There is a need to develop a new generation of biomedical technologies that 
take advantage of evolution and comparative physiology. Hibernation is an obvious 
mammalian adaptation that could support the development of new therapeutic 
regimes for the treatment of human ailments (Bouma, Verhaag et al. 2012; Carey, 
Martin et al. 2012; Saey 2012). In the last few years, the mechanisms underlying a 
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variety of pathways involved in the regulation of hibernation physiology, both 
during euthermia and torpor, have been elucidated, shining light into potential 
targets for therapeutic intervention. Furthermore, due to the extended periods of 
dormancy, the mechanisms by which the hibernating animal avoids morbidity and 
mortality are used chronically (long-term) without evident side effects, which 
cannot be said for the majority of drugs currently in the pharmaceutical market. 
However, only a handful of research teams are exploring the application of 
hibernation strategies for the resolution of human ailments. The focus of the 
research presented here is the development of new treatments and curative 
strategies based on hibernation physiology, particularly for hemorrhagic shock 
scenarios. 
In this introductory section, first I will briefly illustrate some examples of 
diseases and conditions that hibernators manage to avoid. Then I will discuss 
hemorrhagic shock at length. Finally, the objective of the research presented in this 
document will be stated. 
Biomedical Applications of Hibernation Strategies 
Eighty-five years ago, the great comparative physiologist August Krogh 
(1929) wrote an eloquent paper in which he described disease as a functional issue 
to which physiological therapeutics must be developed. Dr. Krogh suggested that 
many of the numerous physiological questions we encounter could be answered by 
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studying the proper animal model, one that has evolved “adaptations of exquisite 
beauty and the most surprising character”. He also acknowledged the need for an 
integrative approach to solving health issues through a collaboration between 
research scientists and clinicians. However, to this day the development of 
biomedical innovations, particularly those based on physiological adaptations of 
wild animals, are few. Furthermore, to our knowledge, there are no Food and Drug 
Administration (FDA) approved therapeutics for human use based on evolutionary 
adaptations such as hibernation despite the existence of a hibernating primate 
(Dausmann, Glos et al. 2004). 
Disuse Muscle Atrophy 
Physical inactivity can result in muscle atrophy. Disuse atrophy is an 
important clinical problem with no effective therapeutic regime (Glass 2003; 
Foletta, White et al. 2011; Bodine 2013). It can be due to a variety of reasons such 
as simple sedentary lifestyle, immobilization (Glass 2003; Jackman and Kandarian 
2004; Lohuis, Harlow et al. 2007; Powers, Kavazis et al. 2007) (e.g. cast), 
suspension (Lohuis, Harlow et al. 2007; Lee, Park et al. 2008) (e.g. sling), bed rest 
(Lohuis, Harlow et al. 2007; Lee, Park et al. 2008), and even spaceflight (Lohuis, 
Harlow et al. 2007; Powers, Kavazis et al. 2007; Lee, Park et al. 2008). 
Normally, muscle mass is maintained by a balance of protein synthesis with 
protein degradation. Disuse results in changes that decrease protein synthesis and 
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increase protein degradation, disrupting the balance required for the maintenance 
of muscle mass and hence leading to loss of myofibrillar content (Hudson and 
Franklin 2002; Lohuis, Harlow et al. 2007; Bodine 2013). 
In non-hibernators, the discontinuance of muscle activity downregulates 
muscle-specific Insulin-like Growth Factor 1 (IGF-1) (Glass 2003; Cai, McCarron 
et al. 2004; Latres, Amini et al. 2005), inhibiting protein synthesis and enhancing 
protein degradation via downstream targets. IGF-1 is important in the activation of 
Phosphoinositide 3-Kinase (PI3K) and subsequently of Protein Kinase B (Akt) 
(Glass 2005; Kandarian and Jackman 2006; Vinciguerra, Musaro et al. 2010). Akt 
is involved in both the inhibition of protein synthesis and the enhancement of 
protein degradation. Inactive Akt promotes myofibrillar degradation by enhancing 
the activity of Fokrhead Box O (FOXO) proteins that induce the expression of 
Atrogin-1/Muscle Atrophy F-box (MAFbx) and Muscle Really Interesting New 
Gene Finger 1 (MuRF1) (Glass 2005; Kandarian and Jackman 2006; Vinciguerra, 
Musaro et al. 2010) which mediate ubiquination. MAFbx and MURF1 are 
considered master genes for muscle wasting and are regarded as the best markers 
for muscle atrophy (Foletta, White et al. 2011; Bodine 2013). Akt inhibits protein 
synthesis when it fails to phosphorylate Mammalian Target of Rapamycin (mTOR), 
a strong mediator of proliferative processes (Glass 2005; Latres, Amini et al. 2005; 
Kandarian and Jackman 2006). Furthermore, though the specific mechanisms have 
not been elucidated yet, immobilization increases oxidative stress. Reactive 
 6 
 
Oxygen Species (ROS) accumulate as they are being produced faster than they can 
be eliminated (Powers, Kavazis et al. 2005), contributing to muscle atrophy via 
different pathways including 1) direct interaction with proteins and disruption of 
their structure and function (Hudson and Franklin 2002), thus making them more 
susceptible as substrates for catabolism; 2) interference with the activation of Akt, 
and hence all of its downstream targets, resulting in decreased protein synthesis 
(Vinciguerra, Musaro et al. 2010); and 3) direct inactivation of Inhibitor of Kappa 
B (IκB), allowing Nuclear Factor Kappa B (NF-κB) (Jackman and Kandarian 2004; 
Kandarian and Jackman 2006) to promote the expression of MAFbx and MURF1 
(Glass 2005; Vinciguerra, Musaro et al. 2010) (Figure 1.1A). 
Hibernators do undergo some loss of muscle mass during periods of 
inactivity. However, it is minimal compared to that experienced by non-hibernating 
organisms (Hudson and Franklin 2002; Lee, Park et al. 2008). Regulatory 
mechanisms exist in hibernators that give them the capacity to overcome muscle 
atrophy due to prolonged dormancy (Figure 1.1B and 1.1C). In most hibernating 
species, protein synthesis is decreased during periods of dormancy for two reasons: 
1) translation cannot occur at the low body temperatures experienced during torpor 
(van Breukelen and Martin 2001) and 2) protein synthesis is costly in energetic 
terms (Bodine 2013). Consequently, most of the mechanisms by which hibernators 
maintain muscle mass must rely on the inhibition of proteolysis. This is supported 
by findings that gene expression and post-translational modifications of the proteins  
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Figure 1.1 Regulation of protein synthesis and degradation in skeletal muscle. 
In humans (A), muscle disuse reduces IGF-1 signaling which affects the PI3K/Akt pathway 
resulting in a reduction of protein synthesis. Furthermore, ROS are generated which enhance protein 
degradation directly and by pathways that promote ubiquination.  Hibernating mammals in torpor 
(B) have the same patterns of reduced protein synthesis that humans exhibit during immobilization. 
However, their antioxidant activity is enhanced which tampers protein degradation due to oxidative 
damage. Furthermore, the master ubiquitin ligases of muscle atrophy, MuRF and MAFbx, are not 
present, impeding protein degradation via ubiquination pathways. During IBAs (C), mTOR activity 
is enhanced, promoting protein synthesis. Line width represents the strength of the interaction. 
Arrowheads represent promotion. Circle heads represent inhibition. 
 
involved in the IGF-1/PI3K/Akt pathway are consistent with atrophy (Cai, 
McCarron et al. 2004; Bodine 2013). However, no changes in MAFbx and MURF1 
have been observed (Rourke, Yokoyama et al. 2004; Lee, So et al. 2010; Barrows, 
Nelson et al. 2011). IBAs have been suggested as a means by which muscle protein 
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synthesis can occur and hence muscle mass can be spared (Lee, Park et al. 2008; 
Bodine 2013). This may be true since the mTOR anabolic pathway increases 
activity during arousal and decreases activity during dormancy (Lee, So et al. 2010; 
Wu and Storey 2012) (Figure 1.1C). 
Markers of oxidative stress are upregulated during hibernation as is NF-κB 
(Carey, Frank et al. 2000). This might seem paradoxical when considering MAFbx 
and MURF1 are not present, or at basal levels, during dormancy. However, NF-κB 
is also involved in the transcription of endogenous antioxidants such as Manganese 
Superoxide Dismutase (MnSOD) (Tanaka, Matsumura et al. 2002; Briganti and 
Picardo 2003), suggesting NF-κB might confer protection against exacerbated 
oxidative damage, hence modulating oxidative stress. 
Finding a treatment for muscular atrophy is the focus of a number of 
research groups (Jackman and Kandarian 2004; Glass 2005; Kandarian and 
Jackman 2006). Some of them use an IGF-1/PI3K/Akt approach (Kaspar, Lladó et 
al. 2003; Stitt, Drujan et al. 2004). For example, they administer IGF-1, maintaining 
activity of all of its downstream targets. Others focus on the modulation of 
oxidative stress as a therapeutic target, particularly on the effect of Vitamin E 
(Appell, Duarte et al. 1997; Servais, Letexier et al. 2007) and other antioxidants 
(McClung, Kavazis et al. 2007). 
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Though many researchers have suggested the investigation and application 
of hibernation strategies to avoid or minimize muscular atrophy (Harlow, Lohuis et 
al. 2001; Hudson and Franklin 2002; Fuster, Busquets et al. 2007), no 
biotranslational studies are currently engaged to our knowledge. 
Disuse Osteopenia 
Bone tissue is in constant turnover, renewing and repairing continuously 
through remodeling. Bone mass is maintained through balanced osteoblastic and 
osteoclastic activities (Komarova, Smith et al. 2003). 
Similarly to muscular disuse atrophy, lack of physical activity may result in 
osteopenia or disuse osteoporosis (Jenkins and Cochran 1969). The absence of 
pressure forces to the bone results in an imbalance in bone remodeling where bone 
resorption exceeding bone formation (Jenkins and Cochran 1969; Sakai 1999; 
Donahue, McGee et al. 2006; McGee-Lawrence, Carey et al. 2008; Alexandre and 
Vico 2011). Despite differences in the mechanisms of bone degradation between 
disuse and postmenopausal osteoporosis (Donahue, Vaughan et al. 2003), the 
current treatment for patients with osteopenia, regardless of cause, are the same 
(Sakai 1999). 
The pathophysiology of immobilization-induced osteopenia is not 
thoroughly elucidated yet. We know that it involves both mechanical and 
endocrine/neuroendocrine cascades. Unloading signals the inhibition of Nitrous 
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Oxide (NO) production (Jenkins and Cochran 1969). Low levels of NO upregulate 
osteoblastic expression of Receptor Activator of NF-κB Ligand (RANKL) which 
promotes osteoclastogenesis and bone resorption (Donahue, McGee et al. 2006; 
Rubin, Rubin et al. 2006; Lau and Guo 2011). Leptin has both osteogenic and anti-
osteogenic functions, depending on where its receptor is expressed (Alexandre and 
Vico 2011; Doherty, Florant et al. 2014). Its osteogenic function involves signaling 
the hypothalamus to stimulate the production of Cocaine and Amphetamine 
Regulated Transcript (CART) protein which downregulates the expression of 
RANKL, inhibiting osteoclast differentiation and bone resorption. The anti-
osteogenic effects of leptin upregulate RANKL, promoting osteoclast 
differentiation and bone resorption. Insulin also plays a role in bone resorption. It 
can directly stimulate leptin release from adipocytes and decrease osteoblastic 
Osteoprotegerin (OPG) expression (Jenkins and Cochran 1969; Cawley, Yanik et 
al. 2010; Doherty, Florant et al. 2014). Since OPG is a decoy receptor of RANK 
(Vega, Maalouf et al. 2007), its downregulation allows increased RANK/RANKL 
binding (Lau and Guo 2011). All the resorptive processes create an acidic milieu in 
the bone that removes a carboxyl group from osteocalcin, creating a positive 
feedback loop with osteoclacin as it increases insulin production in the β-cells of 
the pancreas (Cawley, Yanik et al. 2010; Doherty, Florant et al. 2014) (Figure 
1.2B). 
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Some bone loss does occur in certain hibernating mammals (e.g. ground 
squirrels, golden hamsters, and little brown bats) (Donahue, Vaughan et al. 2003; 
Donahue, Galley et al. 2006; Donahue, McGee et al. 2006). However, at least two 
species of bears preserve bone mass and structure despite long periods of 
immobilization by maintaining a balance in the remodeling processes (Donahue, 
Vaughan et al. 2003; Donahue, McGee et al. 2006; McGee-Lawrence, Carey et al. 
2008; McGee-Lawrence, Wojda et al. 2009; Alexandre and Vico 2011). Identifying 
how hibernators overcome bone loss during unloading could lead to the 
development therapeutics for osteopenia. 
Because there is a difference in hormone patterns between hibernating 
species, it is difficult to draw generalized conclusions for all hibernators. For that 
reason, and since bears seem impervious to disuse-induced osteopenia, we will 
describe some of the mechanisms involved in the maintenance of bone tissue in the 
hibernating bear (Figure 1.2C).  
The skeleton of bears somehow perceives that it is loaded during 
hibernation (Seger, Cross et al. 2011), maintaining a constant production of NO 
(Doherty, Florant et al. 2014). Osteogenic leptin is increased in early hibernation 
(Donahue, McGee et al. 2006; Doherty, Florant et al. 2014), upregulating CART 
expression and maintaining RANKL expression at low levels (Doherty, Florant et 
al. 2014). Insulin levels are low during hibernation (Bradford 2010; Doherty, 
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Florant et al. 2014), impeding insulin-induced downregulation of OPG expression. 
These mechanism work in coordination to maintain a balance between osteoblastic 
and osteoclastic activities and hence preserve bone mass. 
The mechanisms of immobilization-induced osteopenia also appear to 
involve Parathyroid Hormone (PTH), a hormone that developed along with the 
evolutionary process that allowed animal development from aquatic to terrestrial 
life (Sakai 1999). Researchers identified 9 amino acid residue differences between 
human PTH (hPTH) and black bear PTH (bbPTH) (Donahue 2009). They have 
successfully cloned and recombinantly produced bbPTH and used it to prevent bone 
loss in a mouse model of Duchenne muscular dystrophy. bbPTH has greater 
osteoanabolic effects than hPTH (Gray, McGee-Lawrence et al. 2012). 
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Figure 1.2. Regulation of bone resorption and bone formation. 
During normal mechanical loading (A), RANKL receives both promoting and inhibitory signals, 
maintaining bone formation and bone resporption in balance. Immobilization in humans (B) 
enhances the promoting signals of RANKL and reduces its inhibitory signals, promoting an 
imbalance favoring bone resorption which results in osteopenia (B). Hibernating bears (C), maintain 
a balance between bone resoprtion and bone formation. However, bone turnover rates are decreased. 
Line width represents the strength of the interaction. Arrowheads represent promotion. Circle heads 
represent inhibition. 
 
Insulin Resistance 
Fat-storing hibernators increase their body mass to volumes that would lead 
to serious metabolic alterations, such as insulin resistance (Bloomgarden 2007; 
Saey 2012). Ample evidence suggest a relationship between obesity-induced 
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insulin resistance and the development of type 2 diabetes (Kadowaki 2000; 
Shulman 2000; Marette 2003; Puigserver and Rodgers 2006; Bloomgarden 2007). 
In a normal physiological state, eating increases in plasma glucose which 
stimulates insulin secretion, promoting glucose metabolism and storage (Puigserver 
and Rodgers 2006) (Figure 1.3A). The interaction of insulin with its receptor 
activates Insulin Receptor Substrates (IRS) which in turn promotes PI3K/Akt 
pathway activation (Shulman 2000; Marette 2003; Puigserver and Rodgers 2006). 
Akt is important in the regulation of plasma glucose levels as it 1) promotes the 
translocation of Glucose Transporter 4 (GLUT4), the insulin regulated glucose 
transporter, to the cell membrane (Shulman 2000; Marette 2003) allowing 
circulating glucose to enter the cells where it can be stored as glycogen in striated 
muscle or as triglycerides in adipose tissue; 2) inhibits mTOR, which 
downregulates IRSs (Bloomgarden 2007); and 3) phosphorylates FOXOs which 
stimulate β-oxidation and gluconeogenesis (Kadowaki 2000). 
Insulin resistance is a pathology characterized by an unsuccessful response 
of target tissues to insulin (Puigserver and Rodgers 2006; Bloomgarden 2007) 
(Figure 1.3B). Insulin production is normal, but the cells cannot use it efficiently, 
hence glucose is not metabolized leading to hyperglycemia (Inzucchi 2002; Marette 
2003). β cells in the pancreas respond by increasing insulin production to 
compensate, contributing to the development of hyperinsulinemia (Bloomgarden 
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2007). Diabetic individuals exhibit impaired Akt activity regardless of expression 
levels (Krook, Roth et al. 1998). This affects both glucose transport and glycogen 
storage. The Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) 
pathway plays an important role in adipocyte differentiation and growth as well as 
β-oxidation (Kubota, Terauchi et al. 1999; Kadowaki 2000; Kadowaki, Hara et al. 
2003). In the diabetic individual, PPAR-γ expression is defective (Barroso, Gurnell 
et al. 1999), leading to impaired lipid metabolism. 
Obesity further contributes to the diabetic phenotype through dyslipidemia 
(Marette 2003). Excess adipose tissue increases circulatory Non-Esterified Fatty 
Acids (NEFA) (Kadowaki 2000; Shulman 2000; Inzucchi 2002) and pro-
inflammatory cytokines such as Tumore Necrosis Factor Alpha (TNF-α) (Shulman 
2000). NEFAs can further contribute to insulin resistance and hyperglycemia by 
increasing gluconeogenesis in the hepatocytes. Both NEFAs (Kadowaki 2000; 
Shulman 2000; Inzucchi 2002) and TNF-α (Kadowaki 2000; Marette 2003) can 
inhibiting IRSs which results in the impediment of the translocation of GLUT4 
from the cytoplasm to the cellular membranes of myocytes. 
Wu et al (Wu, Biggar et al. 2013) have published a thorough review of 
insulin resistance in hibernating squirrels from which he have adapted for our 
Figure 1.3B. In summary, hyperphagia is observed in the months prior to 
hibernation in order to increase metabolic fuel storage (i.e. adipose triglycerides). 
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Hyperinsulinemia is observed in Ictidomys spp., with circulating insulin levels 
being 4 and 4.5 times higher than the summer active state in pre-hibernation and 
early hibernation, respectively. As hibernation progresses, insulin returns to basal 
levels, reversing the insulin resistant state (Figure 1.3C). The main mechanism 
involved in the reversibility of insulin resistance is an enhanced lipid metabolism. 
This is in contrast to diabetic individuals, who exhibit defective lipolysis. 
The PI3K/Akt and PPAR-γ pathways seem to be the key players in the 
reversibility of insulin resistance in hibernators. Akt activity is diminished 
(Abnous, Dieni et al. 2008; McMullen and Hallenbeck 2010) while PPAR-γ 
expression is upregulated (Eddy, Morin et al. 2005) in torpid squirrels. Immediately 
upon arousal, both from hibernation in the early spring and during IBAs, Akt 
activity is enhanced (McMullen and Hallenbeck 2010). These changes suggest 
hibernators can readily shift their use in metabolic fuel by switching from 
carbohydrate to lipid metabolism throughout the hibernation season, exhibiting 
insulin resistance when fat metabolism is favored and heightening insulin 
sensitivity when glucose utilization is preferred. 
It has been widely suggested that hibernating organisms should be used as 
models of reversible insulin resistance (Bloomgarden 2007; Martin 2008). 
However, to our knowledge there are no translational studies exploring the use of 
hibernation strategies for the treatment of obesity-induced insulin resistance and 
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type 2 diabetes. Currently, glycemic control is the standard of care in order to 
reduce the occurrence of diabetes (Inzucchi 2002). 
A 
 
B 
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Figure 1.3. Insulin signaling. 
In normal insulin signaling (A), increases in blood glucose stimulate insulin production which, 
through an interaction with its receptor in target tissues, promotes a cascade that results in the 
mobilization of GLUT4 to the cell membrane so that blood glucose is internalized by the cells and 
metabolized. During obesity-induced insulin resistance (B), hypertrophied adipocytes promote 
signals that interfere with glucose transport. Also, though insulin is produced, its receptor on the 
target tissues cannot respond to its signal, further interfering with glucose transport. Insulin 
resistance seems to be reversed (C) in hibernating ground squirrels. As their hypertrophied 
adipocytes reduce their size due to the use of fat storage as fuel source, the adipose signals that 
interfere with glucose transport lose strength. Furthermore, the target tissues regain their ability to 
respond to insulin signaling and glucose transport is restored. Line width represents the strength of 
the interaction. Arrowheads represent promotion. Circle heads represent inhibition. Diamond heads 
represent a resistance of the receptor to its substrate. 
Organ Preservation 
The only current treatment for end stage organ disease is transplantation 
(Jahania, Sanchez et al. 1999). In the 1970s, the prognosis for this procedure was 
limited by the immune reaction of the host body to the transplanted organ. As 
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immunosupressive drugs were developed and histocompatibility testing became 
available, organ rejection stopped being a limiting factor (Southard and Belzer 
1995). Nowadays, tissue and organ transplantation is limited by their viability after 
storage. 
There are two main techniques for organ preservation for transplantation 1) 
continuous/intermittent infusion and 2) cold static storage. Despite continuous 
infusion consistently proving to be the superior technique of the two, logistic and 
cost-associated constrains have made static storage the most widely used method 
for preserving organs (Mühlbacher, Langer et al. 1999; Rudd and Dobson 2009). 
Regardless of the technique, a storage solution is needed in order to perpetuate the 
viability of harvested organs. Currently, there are 167 storage solutions available in 
the US (Rudd and Dobson 2009) and none of them are considered an ideal medium 
(Southard and Belzer 1995). However, the University of Wisconsin (UW) solution 
is presently the “golden standard” for liver, kidney, and pancreas storage 
(Mühlbacher, Langer et al. 1999) as it is successful at keeping them viable for two 
days, three days, and three days, respectively (Southard and Belzer 1995). The true 
challenges for the available storage strategies are heart and lung, as neither is viable 
after 6 hours of cold static storage (Southard and Belzer 1995). 
Presently, the mechanisms employed in preservation solutions for cold 
static storage rely on hypothermia to decrease metabolic activity, membrane 
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depolarization to reduce electrical and mechanical activity, impermeability to 
minimize cell swelling and extracellular edema, buffering to prevent acidosis, and 
antioxidants to limit reperfusion injury (Mühlbacher, Langer et al. 1999). There are 
a number of problems still unresolved with this approach such as Adenosine 
Triphosphate (ATP) depletion, ionic imbalance, and capillary collapse, among 
others (Southard and Belzer 1995). These issues limit tissue availability which in 
turn restricts the scope of organ transplantation. 
A few groups have discovered the ability of bowel (Carey, Mangino et al. 
2001), kidney (Green 1999), and liver (Lindell, Klahn et al. 2005) of hibernating 
animals to remain viable after extended periods of storage. However, those studies 
did not attempt to preserve organs from non-hibernating mammals borrowing from 
hibernation physiology; they only concluded that indeed the hibernation phenotype 
is more resistant to extended organ preservation. Most of the work done on the use 
of hibernation physiology for the preservation of organs for transplantation was 
done in the 1990s. In that time, much attention was given to what is now known as 
a Hibernation Induction Trigger (HIT) molecule – an 88 kDa opioid-like molecule 
capable of inducing torpidity in summer active hibernating species as well as in 
animals that do not naturally hibernate (Horton, Kaftani et al. 1998) first identified 
in 1969 (Dawe and Spurrier 1969). A few models of organ preservation using this 
HIT molecule (Oeltgen 1990; Chien, Oeltgen et al. 1991; Oeltgen, Horton et al. 
1996; Bolling MD, Tramontini et al. 1997) and/or D-Ala2-D-Leu5-Enkephalin 
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(DADLE) (Oeltgen 1990; Oeltgen, Horton et al. 1996; Bolling MD, Tramontini et 
al. 1997; Bolling, Su et al. 1997), a supposed agonist, were developed, yet only one 
study conducted orthotopic transplantations (Oeltgen, Horton et al. 1996). In such 
study, lungs from dogs were successfully preserved with HIT-containing plasma 
from woodchucks for up to 33 hours and then transplanted with unaffected lung 
function. Nonetheless, all the experiments involving the HIT molecule are very 
controversial as its identification is regarded as an artifact (Dobson 2004). More 
contemporary experiments using hibernation strategies have not been particularly 
focused on extending preservation times but in completely changing the paradigm 
of organ transplantation by focusing on maintaining tissue viability in warm (Rudd 
and Dobson 2009) non-depolarizing conditions (Rudd and Dobson 2009; Rudd and 
Dobson 2011). 
Hemorrhagic Shock 
Every single person in the world is at risk of trauma regardless of social 
standing, race, religion, or political ideology. From an epidemiological perspective, 
in the United States, traumatic injury is the main cause of death amongst individuals 
ranging from the age of 1 to the age of 44. In the year 2000, this was attributable to 
the expenditure of $117 billion on medical care; 10% of the total US medical 
expenses. Worldwide, 5 million people had trauma-related deaths in 2000 (Kauvar 
and Wade 2005). 
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Hemorrhage is a problem of utmost importance in traumatic injury. 
Hemorrhagic shock makes bodily tissues become ischemic (Deitch 1992; 
Chatterjee, Patel et al. 2002; Kreimeier and Messmer 2002; Serafín, Roselló-
Catafau et al. 2002; Powers, Zurawska et al. 2005; Fink, Hayes et al. 2008) and 
upon resuscitation aimed at the restoration of plasma volume, the reperfusion of 
tissues triggers an inflammatory cascade with subsequent organ failure and death 
(Deitch 1992; Yao, Redl et al. 1998; Rotstein 2000; Keel and Trentz 2005). The 
effective control of hemorrhage and the development of more efficient resuscitation 
strategies can save lives (Alam, Koustova et al. 2005). 
By definition, hemorrhagic shock is the acute reduction of blood volume 
resulting in ischemia, the hypoperfusion of vital organs, and is evidenced by a 
dramatic reduction in cardiac output and arterial blood pressure. A consequence of 
hypoperfused tissues is a reduction in oxygen delivery so that aerobic metabolism 
can no longer be maintained, hence there is a shift to anaerobic metabolism. 
Anaerobic metabolism is not as efficient in ATP production as aerobic metabolism 
(Guyton and Hall 2001). Furthermore, during ischemia, ATP is catabolized to 
hypoxantine (Korthuis, Granger et al. 1985; Pacher, Nivorozhkin et al. 2006). If 
these conditions persist eventually ATP is depleted, resulting in cellular 
dysfunction and death. 
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Further complicating the ischemic event is the fact that the restoration of 
circulation after enduring low oxygen conditions results in oxidative stress known 
as reperfusion injury. Upon the reintroduction of normal oxygen levels, xanthine 
oxidase metabolizes hypoxantine into xanthine and then uric acid, generating 
superoxide and hydrogen peroxide (Korthuis, Granger et al. 1985; Pacher, 
Nivorozhkin et al. 2006). These ROS can cause direct injury to Deoxyribonucleic 
Acid (DNA) and proteins and induce apoptosis (Cooke, Evans et al. 2003; Sanada, 
Komuro et al. 2011). ROS can also open the mitochondrial permeability transition 
(MPT) pore (Kim, Jin et al. 2006) which can further reduce ATP production 
(Stavrovskaya and Kristal 2005). 
Hemorrhagic Shock and Hibernation 
Hibernators survive sluggish circulation followed by brief periods of 
increased heart rate and cardiac output during IBAs many times throughout the 
hibernation season without exhibiting the detrimental effects of ischemia (D'Alecy, 
Lundy et al. 1990) and reperfusion injury (Andrews 2007). Though the hibernating 
state is not accompanied by massive loss of blood, it exemplifies a remarkable 
physiological state characterized by a reduction in cardiac output and blood 
pressure comparable in magnitude to hemorrhagic shock. Furthermore, the classic 
hibernation patterns discussed earlier of cycles of torpidity scattered with IBAs 
closely resemble a number of ischemia/reperfusion events throughout the 
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hibernation season. Peculiarly, the brain and other tissues of hibernators are 
naturally shielded from ischemia (D'Alecy 1990) and reperfusion injury during 
arousal (Andrews 2007). Such protection is achieved by the employment of an array 
of inherent adaptations present in the hibernating animal (Graf and Schaller 2004). 
Currently Available Resuscitative Strategies 
Currently, resuscitation aims to restore intravascular volume and, in turn, 
blood pressure and systemic perfusion, preserving organ function. Taking into 
account both the hemorrhagic insult and the downfalls of resuscitation, the ideal 
resuscitative strategy would include the administration of a fluid that is effective at 
small infusion volumes, can be administered rapidly, has sustained effects, and does 
not cause further complications (Kyes and Johnson 2011). 
Isotonic Resuscitation 
Presently, the standard of care for hemorrhagic shock is based on studies 
performed between 1964 and 1975 by the groups of Shires (Shires, Coln et al. 1964; 
Shires, Carrico et al. 1970), Moyer (Dillon, Lynch Jr et al. 1966), and Moss 
(Cervera and Moss 1975). This guideline indicates the infusion of Lactated 
Ringer’s (LR) in three times the shed blood volume. LR is effective at restoring 
blood pressure and increases cardiac output. However, large volumes are required 
which, as a result, do not allow for fast administration. Furthermore, since LR 
rapidly re-distributes through the extravascular space (Kyes and Johnson 2011), 
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continuous administration is required to observe sustained effects. Additionally, it 
can promote organ dysfunction and failure, boosting inflammation (Moore, 
McKinley et al. 2004). For these reasons, the clinical approaches for resuscitation 
are in continuous re-assessment. 
Hypertonic Resuscitation 
Hypertonic resuscitation was first explored in the 1960s but it was not until 
the 1980s when interest in this resuscitative strategy germinated. In fact, the term 
“small-volume resuscitation” was not forged until 1984 (Nakayama, Sibley et al. 
1984) and the first human experiments were not conducted until 1987 (Holcroft, 
Vassar et al. 1987). The purpose of the administration of small-volume resuscitation 
fluids is primarily to treat trauma and shock patients (Kreimeier and Messmer 
2002).  
Despite the use of small-volume resuscitation fluids having proved 
beneficial in both the experimental and the clinical settings and their providing a 
more practical and sound strategy compared to the current standard of care 
(Kreimeier and Messmer 2002), they are still not being widely employed. 
Furthermore, there is no general agreement in the clinical setting as to which fluid 
therapy provides the most benefit (Angele, Schneider et al. 2008). 
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Hibernation-Based Resuscitation Fluids 
Two research groups (Klein, Wendroth et al. 2010; Letson and Dobson 
2011) are working on the development of hibernation-based resuscitation fluids for 
the treatment of hemorrhagic shock. Letson and Dobson (2011a; 2011b) have also 
borrowed from the hibernating animals to protect against ischemia-reperfusion 
injury by maintaining membrane potential (Dobson 2004). They have developed an 
additive for resuscitation that has been successful at improving survival both in rat 
(Letson and Dobson 2011; Letson and Dobson 2011) and pig (Granfeldt, Nielsen 
et al. 2012) models of hemorrhagic shock. In 2010, Klein et al (Klein, Wendroth et 
al. 2010) developed a small-volume resuscitation fluid. This fluid, called BHB/M, 
utilizing the hibernation protective strategies of hypothermia, use of an alternative 
fuel source, and increased antioxidant defense has proven effective in expanding 
the golden hour and achieving long-term (10 day) survival after blood return in a 
rat model of hemorrhagic shock. The same solution has been tested in a porcine 
model and a survival benefit was observed (Mulier, Lexcen et al. 2012).  
BHB/M 
The therapeutic effects of BHB/M can be attributable to many of its 
characteristics. For example, it is hyperosmolar, which probably increases plasma 
volume and organ perfusion (Nakayama, Sibley et al. 1984; Kreimeier, Brueckner 
et al. 1990; Krausz, Bar-Ziv et al. 1992; Kreimeier and Messmer 2002; Rocha-e-
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Silva and Poli de Figueiredo 2005). Also, melatonin, one of its main components, 
is believed to scavenge reactive oxygen species generated during reperfusion 
(Zang, Cosma et al. 1998; Reiter, Tan et al. 2001; Tan, Manchester et al. 2007; 
Mathes, Kubulus et al. 2008). Furthermore, β-hydroxybutyrate, another main 
component, can reduce glucose utilization by serving as an alternative fuel source 
(Ide, Steinke et al. 1969; Krilowicz 1985; Isaad, Penicaud et al. 1987; Bartlett and 
Eaton 2004). 
D-β-Hydroxybutyrate (BHB) 
BHB is a ketone body, a by-product of fat metabolism. When hibernating 
mammals go through periods of inactivity, they rely on the energy stored in adipose 
tissue to fulfill their metabolic needs. This ketone body acts as an alternative fuel 
source by replacing glucose in energetic pathways, allowing the body to conserve 
energy, preserve cell function, and sustain life (Krilowicz 1985). 
One of the main outcomes of hemorrhagic shock is ATP depletion which 
leads to cell death (Guyton and Hall 2001). BHB dehydrogenase can turn BHB into 
acetoacetate which can borrow a coenzyme-A (CoA) group from succinyl-CoA 
with the help of a transferase enzyme. Acetoacetate-CoA can then be turned into 
two acetyl-CoA molecules which can maintain ATP production (Kashiwaya, 
Takeshima et al. 2000). Hence, a single molecule of BHB is just as energy efficient 
as a molecule of glucose. This is particularly important in ischemic events since 
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glucose can only be converted to acetyl-CoA in aerobic conditions (Nelson, 
Lehninger et al. 2008). 
Melatonin 
Melatonin, a naturally-occurring pineal gland hormone, protects against 
injury by actively scavenging for pro-oxidative molecules, which can damage cell 
membranes and induce cell death, and modulating the immune response (Drew, 
Rice et al. 2001; Methes, Kubulus et al. 2008; Yang, Subeq et al. 2010). Hibernators 
have an almost 4-fold increase in endogenous melatonin levels during arousal from 
torpor compared to their active stages (Larkin, Yellon et al. 2003). Melatonin is a 
powerful antioxidant and free radical scavenger. Reperfusion of an ischemic cell 
generates reactive oxygen species (ROS), which can damage cell membranes, 
directly injure DNA and proteins, and exacerbate inflammatory processes (Cooke, 
Evans et al. 2003; Sanada, Komuro et al. 2011), all of which lead to apoptosis. 
Melatonin can neutralize ROS, minimizing reperfusion injury. Furthermore, the 
products of its reaction with free radicals, N1-acetyl-N2-formyl-5-
methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), also 
possess antioxidant properties (Mayo, Sainz et al. 2005). 
Dimethyl sulfoxide (DMSO) 
Since melatonin is highly hydrophobic and difficult to get into solution, 
DMSO is used as a solvent. There is much controversy over its use, though. In 
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November 1965, a woman in Ireland, who was taking a variety of therapeutic 
agents, including DMSO, died of an allergic reaction. The Wall Street Journal 
published in December 1965 an article entitled “DMSO may have caused death of 
woman, makers of 'Wonder' drug warn doctors” (Carley 1965). In January 1966, 
the FDA banned clinical trials in the United States, mentioning the woman's death 
as a reason. Clinical research using DMSO was ceased and did not resume until 
1972. However, its use is still contentious. 
Objective 
Only one concentration of each one of the components of BHB/M has been 
tested. For that reason, I operate under the hypothesis that enhancing the 
composition BHB/M will improve survival in a rat model of hemorrhagic shock. 
The objective of the work here presented is to optimize the composition and 
delivery of BHB/M. This objective will be achieved by a series of experiments in 
which both hypertonic and isotonic solutions will be administered. 
In the hypertonic experiments, we will 1) evaluate two different modes of 
infusion and 2) conduct dose-ranging studies for the two main components of 
BHB/M: BHB and melatonin. A brief pilot study evaluating the hypothermia-
promoting properties of 3-iodothyronamine (T1AM) will also be described. The 
isotonic experiments will be comprised of a comparison of a larger volume, lower 
molarity BHB/M to Lactated Ringer’s. 
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CHAPTER II: MATERIALS AND METHODS 
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Animals 
Male Sprague-Dawley rats were obtained from Charles River Laboratories 
International, Inc. (Portage, MI). They were housed in pairs in plastic cages, fed 
Laboratory Rodent Diet 5001 (LabDiet. St Louis, MO) ad libidum, provided with 
free access to water, and kept on a 12:12 light/dark cycle. All animals were allowed 
to acclimate to our Research Animal Resources facilities for at least three days 
before conducting experiments. The study was approved by the University of 
Minnesota Institutional Animal Care and Use Committee. 
Anesthesia 
Rats were anesthetized with an inhaled anesthetic. Induction was conducted 
in an induction chamber with isoflurane (Clipper Distributing Company, LLC. St. 
Joseph, MO) at 5% in Breathing Grade Air (19.5%-23.5% Oxygen, ≤ 10 ppm 
Carbon Monoxide, ≤ 1000 ppm Carbon Dioxide, ≤ 24 ppm Water. Praxair 
Technology, Inc. Duluth, MN) at 1 l/min. Maintenance anesthesia was supported 
with ≤2% isoflurane, depending on individual requirements, through a rodent 
anesthesia mask. Both the induction chamber and the mask were connected to a 
vaporizer (Model 61020-SYS. Texas Scientific Instruments, LLC. Boerne, TX). 
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Surgical Cannulation 
Animals were placed on supine position on a surgical board (Model 510-
SS. Plas-Labs, Inc. Lansing, MI) and restrained with quick-tie nylon cords. After 
sterile preparation, a skin incision 1 cm in length was made on the left hind limb at 
the level of the adductor muscles (longus and magnus) 45 degrees to the mid line 
(Figure 2.1A). Then, fascia was removed (Figure 2.1B) and the femoral artery, vein, 
and nerve were exposed (Figure 2.1C) and separated using McPherson angled 
micro forceps (Model RS-5175. Roboz Surgical Instrument Co. Gaithersburg, MD) 
(Figure 2.1D). Vascular micro clips (Model RS-5424. Roboz Surgical Instrument 
Co. Gaithersburg, MD) were placed both proximally and distally on each vessel for 
tourniquet action (Figure 2.1E). Commercially available 24 GA I.V. catheters 
(Model 381412. BD Medical. Sandy, UT) were inserted into the left vein at a ~30 
degree angle to initially perforate the vessel and then flattened to a position as close 
to a 0 degree angle as possible (Figure 2.1F). The catheter was furthered until it 
reached the proximally placed vascular clip. The previously tied piece of silk was 
slightly tightened to secure the catheter and the flash chamber was removed (Figure 
2.1G). At this point, extension tubing was connected to the catheter. Vascular clips 
were removed, the catheter was advanced until fully inserted, and the silk tie was 
further tightened (Figure 2.1H). The left and right femoral arteries were prepared 
similarly. The left vein was employed for whole animal heparinization (10 IU) and 
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for fluid administration; the left artery, for blood pressure monitoring; and the right 
artery, for blood withdrawal. 
A       B 
 
C       D 
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Figure 2.1. Surgical Cannulation Procedure. 
(A) The hind limb is incised, (B) then the skin, subcutaneous tissue and muscle are separated, (C) 
allowing for visualization of the neurovascular package. (D) The nerve, vein, and artery are 
separated next. (E) Tourniquets and a tie for the cannula are placed, (F) leaving the vessel ready to 
be perforated with the cannula. (G) Then the cannula is secured and furthered and the needle, flash 
chamber, and safety chamber of the cannula are removed. (H) Finally, the tourniquets are removed. 
 
Blood Volume Calculation 
Blood volume (ml) was calculated as 6% of the body mass (g) plus 0.77 ml 
as per Lee and Blaufox (1985). This formula accounts for allometric differences in 
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blood volume as smaller animals have larger blood volumes relative to their size 
than larger animals. 
Previously, Klein et al (2010) had used 6% of the body mass as the 
calculated blood volume. However, in the literature, the blood volume of the rat 
ranges anywhere from 6 to 10% of its body mass (Krinke, Bullock et al. 2000). 
With our surgical procedure, we found that when 60% of the blood volume 
was removed using 6% of the body mass to calculate total blood volume, the 
hemorrhagic insult was not enough to ensure any deaths within 24 hours. However, 
when 7% of the body mass was used in the calculation, the hemorrhagic insult was 
too great and none of the animals survived particularly long. Using Lee and 
Blaufox’s (1985) method resulted in nicely distributed survival/defunction times. 
Furthermore, using the 6% of the body mass plus 0.77 mL formula, the withdrawal 
of 40% of the calculated blood volume consistently resulted in a mean arterial blood 
pressure (MAP) of 25 mmHg (Appendix I) 
Induction of Hemorrhagic Shock 
Optimization of Delivery 
Bolus Only Experiments 
Following surgical cannulation, hypotension was achieved by reaching a 
mean arterial blood pressure (MAP) of 25 mmHg, which roughly corresponds to 
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the withdrawal of 40% of the calculated blood volume, over a 10-minute period. 
After the first hemorrhagic phase, a bolus infusion (1 ml/kg) of the published 
formulation of BHB/M was infused also over a 10-minute period. Hypotension was 
then resumed to achieve a total blood loss of 60% of the calculated blood volume. 
Blood samples were collected at four time points: 1) before hypotension (T0), 2) 
after 40% blood loss (T10), 3) 10 minutes after 40% blood loss (T20), and 4) after 
60% blood loss (T30). Animals were monitored for 24 hours. A timeline of the 
hemorrhagic protocol is illustrated in Figure 2.2A. 
Bolus Only plus Slow Infusion Experiments 
Hemorrhagic shock was induced similarly to the Bolus Only protocol 
above, except that after the bolus administration and before resuming hypotension 
we initiated a slow infusion (100 µL/Kg) stage which was sustained for one hour. 
Blood samples were collected at five time points: 1) before hypotension (T0), 2) 
after 40% blood loss (T10), 3) 10 minutes after 40% blood loss (T20), 4) after 60% 
blood loss (T30), and 5) one hour after 60% blood loss (T90). This hemorrhagic 
shock protocol is depicted in Figure 2.2B. 
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Figure 2.2 Optimization of delivery experiments: Experimental timeline. 
After surgical preparation, animals were hemorrhaged until MAP ~25mmHg. They were then 
infused with either a single 1 ml/kg bolus (A) or a bolus followed by a 100 µL/hr slow infusion (B). 
In both instances, the bolus infusion was administered within 10 minutes. After bolus 
administration, animals were further hemorrhaged to 60% of their calculated blood volume. No 
blood was transfused at any time point. Animals were monitored for 24 hours. All 24-hour survivors 
were euthanized. 
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Optimization of Composition 
Hypertonic Resuscitation Experiments 
The hemorrhagic shock protocol for all the experiments in this section was 
identical. It is very similar to the protocol described in the Bolus Only section 
above. It differs in that 50% of the shed blood was returned one hour after achieving 
60% blood loss at a rate of 500 µl/min. Blood samples were collected at six time 
points: 1) before hypotension (T0), 2) after 40% blood loss (T10), 3) 10 minutes 
after 40% blood loss (T20), 4) after 60% blood loss (T30), 5) one hour after 60% 
blood loss (T90), and 6) after blood return (T105). Animals were monitored for 10 
days. A timeline of this protocol is represented in Figure 2.3. 
 
Figure 2.3. Hypertonic resuscitation experiments: Experimental timeline. 
After surgical preparation, animals were hemorrhaged until MAP ~25mmHg and infused with a 
single 1 ml/kg bolus of solution over a 10 minute period. After bolus administration, animals were 
further hemorrhaged to 60% of their calculated blood volume and maintained in a shocked state for 
one hour. 50% of the shed blood volume was autotransfused at a rate of 500 µl/min 60 minutes after 
achieving 60% blood loss. Animals were monitored for 10 days. All 10-day survivors were 
euthanized. 
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Isotonic Resuscitation Experiments 
One-Hour Hemorrhagic Shock 
Immediately after surgical instrumentation, blood was withdrawn via the 
right artery over 10 minutes until a MAP of 25 mmHg was obtained. Hypotension 
was paused for 10 minutes after which blood withdrawal resumed to achieve a total 
blood loss of 60% of the calculated blood volume. Immediately after achieving 
60% blood loss, an infusion was started at a rate of 3 time the volume lost per hour 
for one hour. Immediately after, 50% of the shed blood was returned at a rate of 
500 µl/min. The same six time point for blood sampling in the Hypertonic 
Resuscitation Experiments described above were used. Figure 2.4A represents the 
timeline for this protocol. 
Three-Hour Hemorrhagic Shock 
60% blood loss was achieved exactly as described for the One-hour 
Hemorrhagic Shock Protocol. Infusion of fluids was conducted at a rate of one time 
the volume lost per hour for three hours. Animals were then autotransfused 50% of 
their shed blood at 500 µl/min. Blood samples were collected at six time points: 1) 
before hypotension (T0), 2) after 40% blood loss (T10), 3) 10 minutes after 40% 
blood loss (T20), 4) after 60% blood loss (T30), 5) three hours after 60% blood loss 
(T210) and 6) after blood return (T225). Figure 2.4B shows this protocol’s timeline. 
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Figure 2.4. Isotonic resuscitation experiments: Experimental timeline. 
After surgical preparation, animals were hemorrhaged until MAP ~25mmHg. After a 10 minute 
period, they were further hemorrhaged to 60% of their calculated blood volume. Then rats were 
administered isotonic solutions at a rate equal to (A) three volumes the shed blood per hour for an 
hour or (B) one volume the shed blood per hour for three hours. 50% of the shed blood volume was 
autotransfused at a rate of 500 µl/min either (A) 60 minutes or (B) 180 minutes after achieving 60% 
blood loss. Animals were monitored for 10 days.  10-day survivors were euthanized. 
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Wound Closure 
After the hemorrhagic shock protocol came to a conclusion, all incisions 
were closed with a single cruciate stitch (internal cross) with 4-0 polypropylene 
suture (Prolene. Model 8521. Ethicon Endo-Surgery, Inc. Cincinnati, OH). 
Experimental Treatments 
All solutions were made fresh daily. The sodium salt form of the D-isomer 
of BHB was obtained from Ariel Pharmaceuticals, Inc. (Broomfield, CO). 
Melatonin was provided by Flamma S.p.A. (Bergamo, Italy). We used DMSO from 
Sigma-Aldrich Co. LLC. (St. Louis, MO). 
Optimization of Composition 
Hypertonic Resuscitation Experiments 
Melatonin Dose-Ranging Study I 
The published formulation of BHB/M containing 4 M BHB, 43 mM 
melatonin and 20% DMSO was compared against a solution containing 4 M BHB, 
4.3 mM melatonin and 10% DMSO. 
BHB Dose-Ranging Study 
Solutions containing 4 M, 2 M, and 0.4 M BHB were compared. All 
solutions contained 4.3 mM melatonin and 10% DMSO. 
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Melatonin Dose-Ranging Study II 
All solutions contained 4 M BHB and 2% DMSO. Melatonin was compared 
at concentrations of 4.3 mM, 0.43 mM, 0.0043 mM, 0.000043 mM, and 0 mM. 
T1AM Pilot Study 
Solutions containing T1AM at concentrations of 50 mg/kg, 25 mg/kg, 10 
mg/kg, 2 mg/kg T1AM), or 0 mg/kg were compared in normotensive (not 
hemorrhaged) animals. 
Isotonic Resuscitation Experiments 
The solutions included in both the One-Hour and the Three-Hour 
Hemorrhagic Shock protocols and their compositions are described in Table 2.1. 
They are four: 1) LR, 2) LR plus 4.3 mM melatonin, 3) 140 mM BHB with 1.5x10-
6 mM melatonin, and 4) 140 mM BHB with 4.3 mM melatonin. 
Table 2.1. Isotonic resuscitation experimental design 
 
Sample size n=10 for all treatment groups. Abbreviations: BHB-β-Hydroxybutyrate. DMSO-
Dimethyl sulfoxide. LR- Lactated Ringer’s. Mel-Melatonin. 
Component LR LR / 4.3 mM Mel
140 mM BHB / 1.5x10-6 
mM Mel
140 mM BHB / 4.3 mM 
Mel
3-D-β-hydroxybutyrate 140 mM 140 mM
D-L-lactate 28 mM 28 mM
Sodium 130 mM 130 mM 140 mM 140 mM
Potassium 4 mM 4 mM
Calcium 3 mM 3 mM
Chloride 109 mM 109 mM
Melatonin 4.3 mM 1.5x10-6 mM 4.3 mM
DMSO 0.2% 0.02% 0.02%
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Monitoring of Physiological Constants 
Mean arterial blood pressure (MAP) and heart rate (HR) were recorded 
continuously via the left femoral artery cannula that was connected to a data 
acquisition device (PowerLab 4/30. ADInstruments, Inc. Colorado Springs, CO). 
Rectal temperature was continuously monitored using a rectal sensor. 
Whole-Blood Parameters 
Each blood sample was ran through a blood gas analyzer (Model ABL815 
Flex. Radiometer America. Westlake, OH) for total hemoglobin (tHb), pH, 
saturation of oxygen (sO2), potassium ion (K
+), sodium ion (Na+), calcium ion 
(Ca++), chloride ion (Cl-), glucose (Glu), and lactate (Lac). For the Optimization of 
Delivery and Hypertonic Resuscitation Experiments, we also obtained partial 
pressure of oxygen (pO2) and partial pressure of carbon dioxide (pCO2). 
Histopathological Scoring 
10-day survivors were euthanized. Their tissues were harvested and fixed 
in 5% paraformaldehyde. We selected the brain, lung, and small intestine for 
histopathological assessment. The specific regions of each tissue are as follow: 
brain at Bregma ~-3, the left inferior lobe of the lung, and a mesenteric portion of 
the jejunum. Tissues were processed in a Model Tissue-Tek VIP 1000 tissue 
processor (Model 4617. Miles Laboratories Inc. Naperville, IL) (Appendix II). 
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They were embedded in paraffin using a Leica embedding center (Model EG1160. 
Leica Microsystems Inc. Buffalo Grove, IL).  5 μm sections were obtained with a 
manual microtome (Model 2030 Biocut. Reichert Inc. Munich, Germany) and 
mounted on StarFrost slides (Model CAS 8448WE. Mercedes Medical. Saratosa, 
FL). Slides were stained with hematoxylin and eosin (H&E) (Appendix III) with an 
autostainer (Model XL. Australian Biomedical Corporation Ltd. Melbourne, 
Australia). Slides were photographed at 20X magnification with an epifluorescence 
microscope (Model Eclipse 80i. Nikon Instruments Inc. Melville, NY) using SPOT 
Basic microscopy imaging software (Version 5.1. SPOT Imaging Solutions. 
Sterling Heights, MI). A scoring system on a 0-3 scale was developed (Table 2.2). 
This system was adapted from that used by Klein et al (2010) for brain, by Turkoglu 
et al (2012) for lung, and by Feinman et al (2010) for intestine. Three areas of the 
hippocampus (CA1, CA2, and CA3 neurons) and five random areas of the lung and 
intestine were examined. Sections were assessed blindly twice with a week in 
between observations and the scores were averaged. 
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Table 2.2. Histopathological scoring system. 
 
Plasma Parameters 
BHB (Appendix IV) and TNF-α (Appendix V) were measured using 
commercially available kits. For BHB we used a colorimetric assay (LiquiColor 
2440. Stanbio Laboratories. Boerne, TX). TNF-α levels were determined using an 
Invitrogen immunoassay (Model KRC3011. Life Technologies. Carlsbad, CA). All 
reactions were conducted according to the manufacturers’ manuals and read in the 
same absorbance microplate reader (SpectraMax Plus384. Molecular Devices, 
LLC. Sunnyvale, CA) using a data acquisition and analysis software (Softmax Pro 
version 5.4. MDS Analytical Technologies. Sunnyvale, CA). When appropriate, 
standard curves were generated and points were fit to a line using a curve fitting 
and data analysis software (CurveExpert Professional version 2.0.4. Hyams 
Development. Chattanooga, Tennessee). 
Lung Intestine Brain
0
1 Mild Alveolitis (2-3X); 
perivascular edema
Development of 
subepithelial Gruenhagen's 
space; vacuolization at the 
villus tip
Focal condensation of 
chromatin in the nucleus 
(pyknosis)
2 Moderate Alveolitis (3-4X); interstitial 
edema
Lifting of epithelial layer 
from the lamina propria; 
increased vacuolization 
from the tip to midportion 
of villi.
Multifocal/diffuse pyknosis
3 Severe Alveolitis (>5X); alveolar 
edema; inflammatory 
infiltrate; hemorrhage
Epithelial lifting and 
vacuolization from the tip to 
lower portion of villi; 
mucosal ulceration and 
disintegration of the lamina 
propria; inflammatory 
infiltrate; hemorrhage
Extensive pyknosis
No Evidence
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Statistical Analyses 
Survival curves were compared in SigmaPlot (version 11.0, Build 
11.0.0.77) using a Gehan-Breslow-Wilcoxon test. Non-inferiority tests were also 
conducted in order to identify survival differences with the published formulation 
of BHB/M. One-way ANOVAs with Tukey’s post hoc test were performed in JMP 
(version 8.0, Build 9200) to find differences between treatments for physiological 
constants, whole blood, and plasma data at each time point. Student’s t-tests were 
used to compare 10-day survivors and non-survivors, regardless of treatment, 
within different time points for physiological constants, whole-blood, and plasma 
data. One-way ANOVAs were also used to establish histopathological score 
differences between treatments. A Cox Proportional Hazards regression model was 
conducted using a phreg procedure in SAS (version 9.4) to identify relationships 
between survival and physiological constants, whole-blood, and plasma data 
independently of treatment. 
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CHAPTER III: HYPERTONIC EXPERIMENTS 
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Survival 
Optimization of Delivery 
Klein et al’s experiments (2010) administered BHB/M as a 1 ml/kg bolus 
followed by a 100 µl/hr slow infusion. We explored the possibility of administering 
BHB/M as a single bolus only. These experiments were conducted in acutely 
operated rats; these animals did not receive a blood transfusion 60% blood loss. No 
statistical differences (p>0.05) were observed in 24-hour survival when comparing 
the bolus only (mean survival 496.67 ± 314.59 min. n=6) to the bolus plus slow 
infusion (mean survival 149.20 ±142.71 min. n=5) protocol (Figure 3.1). For this 
reason, all further experiments were conducted administering a single 1 ml/kg 
bolus. 
 
Figure 3.1. Optimization of delivery experiments: Kaplan-Meier plot of animals subjected to 
60% blood loss. 
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Infusion of the published formulation of BHB/M was conducted either by administering either a 
single 1 ml/kg bolus (n=6) or a bolus followed by a 100 µL/hr slow infusion (n=5). The groups were 
not statistically different from each other. Times on the x-axis reflect minutes after achieving 60% 
blood loss. Some lines may be indistinguishable due to overlap. 
Optimization of Composition 
Melatonin Dose-Ranging Study I 
We decided to do a comparison between the published concentration of 
melatonin in BHB/M (43 mM), and a 10-fold decrease for two reason. Firstly, 
serum melatonin peaks in rats are ~8.61 × 10-7 mM (Benot, Molinero et al. 1998). 
Administering 43 mM melatonin at ml/kg would result in an overall bodily 
concentration of melatonin of .043 mM, almost fifty thousand times that of the peak 
physiological concentrations. Secondly, DMSO in this therapy acts simply as a 
solvent for melatonin and does not seem to provide any additional therapeutic 
benefits (Klein, Wendroth et al. 2010). Furthermore, its use is very controversial. 
A simple 10-fold decrease in the melatonin concentration administered would allow 
for DMSO to be lowered to 2% of the final volume. Hence, making our formulation 
less polemical than it needs to be. 
The published formulation of BHB/M (n=6) was compared to a solution 
containing 4 M BHB, 4.3 mM melatonin and 10% DMSO (n=6). A group of 
animals (n=10) underwent a sham operation in which all the surgical procedures 
for femoral cannulation were conducted but the only blood drawn was for sampling 
(~6% blood loss).  
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Survival curves were compared at 24 hours and 10 days after 60% blood 
loss. 24-hour survival showed no statistical differences (p>0.05) between BHB/M 
(mean survival 21.00 ± 2.74 hrs) and 4 M BHB, 4.3 mM melatonin and 10% DMSO 
(mean survival 21.00 ± 2.74 hrs). There were also no statistical differences (p>0.05) 
in survival at 10 days (6.38 ± 2.00 days and 7.38 ± 1.75 days, respectively) (Figure 
3.2; Table 3.1). All sham-operated rats lived to the experimental end point of 10 
days. 
Table 3.1. Melatonin Dose-Ranging Study I: Mean survival time in animals subjected to 60% 
blood loss at 24 hours and 10 days. 
 
Units are hours for the calculations at 24 hours (corresponding to Figure 3.2A) and days for the 
calculations at 10 days (corresponding to Figure 3.2B). The treatment labeled as 43 mM Mel 
contains 4 M BHB with 43 mM melatonin in 20% DMSO (n=6); the treatment labeled as 4.3 mM 
Mel contains 4 M BHB with 4.3 mM melatonin in 10% DMSO (n=6). Statistically significant p-
values are colored in red and underlined. Abbreviations: Mel-melatonin. 
BHB Dose-Ranging Study 
After establishing that 4.3 mM melatonin had the same therapeutic effect as 
43 mM melatonin, we explored the possibility of administering lower 
24 Hrs 10 Days
21.00 ± 2.74 7.375 ± 1.75
21.00 ± 2.74 6.375 ± 2.00
24.00 10.00
24 Hrs 10 Days
4.3 mM Mel 43 mM Mel 1.0000 0.7980
4.3 mM Mel Sham 0.1760 0.0143
43 mM Mel Sham 0.1760 0.0143
Mean ± SEM
p -value
4.3 mM Mel
43 mM Mel
Sham
Treatment Comparisons
Treatment
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concentrations of BHB. In these experiments, all treatments contained 4.3 mM 
melatonin and were dissolved in 2% DMSO. 
BHB concentrations of 4 M (n=6), 2 M (n=5) and 0.4 M (n=5) were 
compared at 24 hours and 10 days after 60% blood loss (Figure 3.3). Table 3.2 
summarizes pairwise comparison results. In short, at 24 hours, the 0.4 treatment 
had statistically lower survival (p<0.05) than the 4 M and the 2 M BHB treatments. 
At 10 days, only the difference between 0.4 M and 4 M BHB was upheld (p<0.05). 
However, 10-day mean survival showed a dose-dependent trend where the higher 
the concentration of BHB the longer the survival (4 M BHB, 7.38 ± 1.75 days; 2 M 
BHB, 5.25 ± 2.22 days; 0.4 M BHB, 2.07 ± 2.05 days). Consequently, all future 
experiments will contain BHB at a 4 M concentration. 
A 
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Figure 3.2. Melatonin Dose-Ranging Study I: Kaplan-Meier plot of animals subjected to 60% 
blood loss at (A) 24 hours and (B) 10 days. 
Infusion of either 4 M BHB with 43 mM melatonin in 20% DMSO (n=6) or 4 M BHB with 4.3 mM 
melatonin in 10% DMSO (n=6) was achieved by administering a single 1 ml/kg bolus. Sham-
operated animals are also included in the graph. Times on the x-axis reflect either hours (A) or days 
(B) after achieving 60% blood loss. Some lines may be indistinguishable due to overlap. 
Non-Inferiority Test 
Not observing statistical differences does not necessarily mean there are no 
practical or biologically relevant dissimilarities. Non-inferiority tests are designed 
to prove that one treatment is indistinguishable from another and their use has 
become a trend in the development of new therapies (Lesaffre 2008; Walker and 
Nowacki 2011). With this in mind, we conducted non-inferiority analyses to 
determine if the new formulations developed in this study are non-inferior to the 
published BHB/M. Non-inferiority was declared if the mean survival for each 
treatment was no worse than the mean survival for the published formulation of 
 55 
 
BHB/M within a threshold difference (Δ) of two days. No treatments stayed within 
the specified boundary (Figure 3.4). 
Table 3.2. BHB Dose-Ranging Study: Mean survival time in animals subjected to 60% blood 
loss at 24 hours and 10 days. 
 
Units are hours for the calculations at 24 hours (corresponding to Figure 3.3A) and days for the 
calculations at 10 days (corresponding to Figure 3.3B). Sample sizes are as follows: 4 M BHB, n=6; 
2 M BHB, n=5; 0.4 M BHB, n=5. All solutions contained 4.3 mM melatonin and 10% DMSO. 
Statistically significant p-values are colored in red and underlined. Abbreviations: BHB-β-
Hydroxybutyrate. 
  
24 Hrs 10 Days
6.50 ± 4.64 2.07 ± 2.05
20.40 ± 3.22 5.25 ± 2.21
21.00 ± 2.74 7.38 ± 1.75
24.00 10.00
24 Hrs 10 Days
0.4 M BHB 2 M BHB 0.0398 0.0803
0.4 M BHB 4 M BHB 0.0222 0.0472
0.4 M BHB Sham 0.0004 0.0004
2 M BHB 4 M BHB 0.8920 0.4990
2 M BHB Sham 0.1380 0.0041
4 M BHB Sham 0.1760 0.0102
Treatment Comparisons
p -value
Sham
Treatment
Mean ± SD
0.4 M BHB
2 M BHB
4 M BHB
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B 
 
Figure 3.3. BHB Dose-Ranging Study: Kaplan-Meier plot of animals subjected to 60% blood 
loss at (A) 24 hours and (B) 10 days. 
Infusion of either 4 M BHB (n=6), 2 M BHB (n=5), or 0.4 M BHB (n=5) was achieved by 
administering a single 1 ml/kg bolus. All solutions contained 4.3 mM melatonin and 10% DMSO. 
Sham-operated animals are also included in the graph. Times on the x-axis reflect either hours (A) 
or days (B) after achieving 60% blood loss. Some lines may be indistinguishable due to overlap. 
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Survival curves for the concentrations of melatonin, depicted in Figure 3.5, 
were compared 24 hours and 10 days after 60% blood loss. Pairwise comparisons 
are summarized in Table 3.3. No treatment differences were observed at either 24 
hours or 10 days after 60% blood loss. However, at 10 days, only the treatments 
with 0 mM melatonin (4.38 ± 1.42 days), 0.0043 mM Mel (6.58 ± 1.60 days), and 
the NaCl control (4.58 ± 1.42 days) were different (p<0.05) from the sham group. 
 
Figure 3.4. BHB Dose-Ranging Study: Non-inferiority plot of animals subjected to 60% blood 
loss at 10 days. 
Infusion of either 4 M BHB (n=6), 2 M BHB (n=5), 0.4 M BHB (n=5), or the published formulation 
of BHB/M (n=8) was achieved by administering a single 1 ml/kg bolus. The published formulation 
of BHB/M contained 4 M BHB, 43 mM melatonin, and 20% DMSO. All other solutions contained 
4.3 mM melatonin and 10% DMSO. Times on the x-axis reflect differences in survival times in days 
after achieving 60% blood loss. Units are expressed as mean survival in days ± 95% Confidence 
Interval 
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Non-Inferiority Test 
We considered a treatment to be non-inferior to the published formulation 
of BHB/M if its mean survival was no worse than that for BHB/M within a Δ of 
two days (Figure 3.6). All combinations of BHB and melatonin stayed within the 
two-day boundary established in order to determine non-inferiority. Only BHB 
alone and the NaCl control were found inferior to the published BHB/M. 
A 
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Figure 3.5. Melatonin Dose-Ranging Study II: Kaplan-Meier plot of animals subjected to 60% 
blood loss at (A) 24 hours and (B) 10 days. 
Infusion of either 4.3 mM melatonin (n=10), 0.43 mM melatonin (n=10), 0.0043 mM melatonin 
(n=10), 0.000043 mM melatonin (n=10), or 0 mM melatonin (n=10) was achieved by administering 
a single 1 ml/kg bolus. All solutions contained 4 M BHB and 2% DMSO. A control group was also 
included and they were administered 4 M NaCl with 0.000043 mM melatonin in 2% DMSO (n=10). 
Sham-operated animals are also included in the graph. The Times on the x-axis reflect either hours 
(A) or days (B) after achieving 60% blood loss. Some lines may be indistinguishable due to overlap. 
Physiological Constants 
MAP, HR and rectal temperature were monitored in real time throughout 
the hemorrhagic protocol. Only experiments where survival differences between 
hemorrhaged groups were observed will be described in this section, with the 
exception of the T1AM pilot study in which depressed body temperature was the 
only parameter monitored. 
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Table 3.3. Melatonin Dose-Ranging Study II: Mean survival time in animals subjected to 60% 
blood loss at 24 hours and 10 days. 
 
Units are hours for the calculations at 24 hours and days for the calculations at 10 days. Sample 
sizes are as follows: 4.3 mM melatonin, n=10; 0.43 mM melatonin, n=10; 0.0043 mM melatonin, 
n=10); 0.000043 mM melatonin, n=10; and 0 mM melatonin, n=10. These solutions contained 4 M 
BHB and 2% DMSO. A control group was also included and they were administered 4 M NaCl with 
0.000043 mM melatonin in 2% DMSO (n=10). Statistically significant p-values are colored in red 
and underlined. Abbreviations: Mel-melatonin. 
24 Hrs 10 Days
18.6 ± 3.20 4.38 ± 1.42
21.71 ± 2.76 7.71 ± 1.10
18.60 ± 3.20 3.58 ± 1.60
22.20 ± 2.30 7.63 ± 1.44
20.40 ± 3.22 7.75 ± 1.49
18.60 ± 3.20 4.58 ± 1.42
24 10.00
24 Hrs 10 Days
Sham 0 mM Mel 0.0555 0.0009
Sham 4.3 mM Mel 0.1280 0.0555
Sham 0.43 mM Mel 0.2940 0.0555
Sham 0.0043 mM Mel 0.0555 0.0229
Sham 0.000043 mM Mel 0.2940 0.0555
Sham NaCl Control 0.0555 0.0009
0 mM Mel 4.3 mM Mel 0.6150 0.1200
0 mM Mel 0.43 mM Mel 0.2760 0.0792
0 mM Mel 0.0043 mM Mel 1.0000 0.3560
0 mM Mel 0.000043 mM Mel 0.3570 0.0864
0 mM Mel NaCl Control 1.0000 0.9080
4.3 mM Mel 0.43 mM Mel 0.5420 0.9630
4.3 mM Mel 0.0043 mM Mel 0.6150 0.5910
4.3 mM Mel 0.000043 mM Mel 0.6260 0.9630
4.3 mM Mel NaCl Control 0.6150 0.1310
0.43 mM Mel 0.0043 mM Mel 0.2760 0.5630
0.43 mM Mel 0.000043 mM Mel 0.9420 1.0000
0.43 mM Mel NaCl Control 0.2760 0.0866
0.0043 mM Mel 0.000043 mM Mel 0.3570 0.6570
0.0043 mM Mel NaCl Control 1.0000 0.3550
0.000043 mM Mel NaCl Control 0.3570 0.0866
Treatment Comparisons
p -value
Treatment
Mean ± SEM
0 mM Mel
0.000043 mM Mel
0.0043 mM Mel
0.43 mM Mel
4.3 mM Mel
NaCl Control
Sham
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Figure 3.6. Melatonin Dose-Ranging Study II: Non-inferiority plot of animals subjected to 
60% blood loss at 10 days. 
Infusion of either 4.3 mM melatonin (n=10), 0.43 mM melatonin (n=10), 0.0043 mM melatonin 
(n=10), 0.000043 mM melatonin (n=10), or 0 mM melatonin (n=10) was achieved by administering 
a single 1 ml/kg bolus. All solutions contained 4 M BHB and 2% DMSO. A control group was also 
included and they were administered 4 M NaCl with 0.000043 mM melatonin in 2% DMSO (n=10). 
All of the aforementioned treatments are being compared to the published formulation of BHB/M 
(n=8) containing 4 M BHB, 43 mM melatonin, and 20% DMSO. Times on the x-axis reflect 
differences in survival times in days after achieving 60% blood loss. Units are expressed as mean 
survival in days ± 95% Confidence Interval. Dashed line represents a threshold difference (Δ) of 
two days. 
Optimization of Composition 
BHB Dose-Ranging Study 
Table  3.4 and Figure 3.7  compile differences between treatments. 
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B      C 
 
Figure 3.7. BHB Dose-Ranging Study: Physiological constant data. 
Infusion of either 4 M BHB (n=6), 2 M BHB (n=5), or 0.4 M BHB (n=5) was achieved by 
administering a single 1 ml/kg bolus. All solutions contained 4.3 mM melatonin and 10% DMSO. 
Times on the x-axis reflect minutes. Data points are depicted as mean ± SEM. 
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Table 3.4. BHB Dose-Ranging Study: Physiological constant data. 
 
Statistical significance is denoted by the presence of different letters. Groups not sharing a letter are statistically different (p<0.05). Abbreviations: 
BHB-β-Hydroxybutyrate. 
 
Sham 99.20 ± 12.00 A 84.77 ± 12.57 A 84.77 ± 12.57 A 84.29 ± 11.70 A 97.45 ± 13.33 A 96.18 ± 12.66 A
4 M BHB 93.38 ± 7.90 A 26.66 ± 3.06 B 54.66 ± 15.69 B 24.94 ± 2.50 B 70.35 ± 18.55 B 105.22 ± 12.78 A
2 M BHB 91.56 ± 9.22 A 26.47 ± 0.66 B 41.01 ± 5.42 B 28.42 ± 5.75 B 75.22 ± 19.64 AB 105.89 ± 11.19 A
0.4 M BHB 95.29 ± 5.03 A 27.27 ± 1.91 B 41.92 ± 10.41 B 26.38 ± 4.27 B 65.57 ± 22.71 B 117.56 ± 9.35 A
Sham 360.32 ± 42.95 A 341.18 ± 56.17 A 333.03 ± 51.95 A 316.69 ± 55.00 A 299.54 ± 20.15 A 291.76 ± 23.90 A
4 M BHB 312.20 ± 112.75 A 208.35 ± 32.46 B 234.86 ± 36.97 B 216.84 ± 28.65 B 260.40 ± 45.33 AB 238.98 ± 40.42 B
2 M BHB 327.85 ± 48.80 A 158.39 ± 24.34 B 188.24 ± 18.09 B 196.41 ± 13.86 B 243.12 ± 46.64 B 237.73 ± 27.70 B
0.4 M BHB 310.76 ± 44.63 A 168.72 ± 35.32 B 202.13 ± 14.96 B 179.89 ±39.96 B 294.55 ± 59.50 AB 257.81 ± 29.07 AB
Sham 35.52 ± 0.37 A 33.83 ±0.48 A 32.86 ± 0.67 A 32.06 ± 0.65 A 29.35 ± 0.56 A 29.03 ± 0.54 A
4 M BHB 35.10 ± 0.62 AB 32.92 ± 1.05 AB 31.19 ± 1.20 B 30.48 ± 1.55 BC 26.01 ± 2.13 B 25.85 ± 1.86 B
2 M BHB 34.40 ± 1.47 B 31.70 ± 1.65 B 30.04 ± 1.53 B 28.89 ± 1.42 C 25.07 ± 1.36 B 24.93 ±1.25 B
0.4 M BHB 34.79 ± 0.73 AB 32.45 ± 0.73 AB 30.67 ± 1.06 B 29.73 ± 1.16 BC 25.18 ± 2.61 B 26.31 ± 0.98 B
MAP (mmHg)
HR (BPM)
Rectal Temperature (°C)
T10 T20 T30
Mean ± SD
Mean ± SD
T105
T90 T105
T0 T10 T20 T30 T90 T105
T0
Mean ± SD
T0 T10 T20 T30 T90
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MAP provides information about systemic perfusion. MAP was higher in 
shams at T10, T20, and T30 (p<0.0001) compared to all hemorrhaged groups. This 
is to be expected as shams only had blood drawn for sampling. At T90, all 
hemorrhaged groups were 20-30 mmHg lower than sham-operated animals. 
However only the published formulation of BHB/M, the treatment with 4 M BHB, 
and the treatment with 0.4 M BHB showed statistical differences (p<0.05) when 
compared to shams. 
HR is an important player in determining cardiac output (CO) and hence 
heart function, blood transport, and oxygen delivery. Shams had higher HR than all 
other treatments at T10 (p<0.0001), T20 (p<0.0001), and T30 (p<0.01). By T90, 
hemorrhaged animals had a HR close to that of shams. 
Monitoring rectal temperature is important for cerebral metabolic rate drop 
6 to 10% per 1°C reduction in body temperature, decreasing glucose utilization and 
oxygen consumption which are significant protective effects of hypothermia 
(Polderman 2009). All animals presented a gradual decrease in rectal temperature 
as a result of anesthesia. However, the reduction in hemorrhaged animals was 
sharper than in shams. 
Melatonin Dose-Ranging Study II 
Treatment differences can be observed in Table 3.5 and Figure 3.8. 
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Figure 3.8. Melatonin Dose-Ranging Study II: Physiological constant data. 
Infusion of either 4.3 mM melatonin (n=10), 0.43 mM melatonin (n=10), 0.0043 mM melatonin 
(n=10), 0.000043 mM melatonin (n=10), or 0 mM melatonin (n=10) was achieved by administering 
a single 1 ml/kg bolus. All solutions contained 4 M BHB and 2% DMSO. A control group was also 
included and they were administered 4 M NaCl with 0.000043 mM melatonin in 2% DMSO (n=10). 
Times on the x-axis reflect minutes. Data points are depicted as mean ± SEM. 
MAP was lower in all treatments compared to shams (p<0.0001) through 
the blood withdrawal phase. During the one-hour hemorrhage period MAP rose 
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steadily to levels close to those of shams. After a blood transfusion, MAP reached 
levels higher than baseline. 
Sham-operated animals had higher HR than all hemorrhaged groups 
through the experiment, with T0 being the exception. 
All groups, including shams, had gradual decreases in rectal temperature 
throughout the experimental protocol. However, sham-operated animals 
consistently showed rectal temperatures a few degrees above all hemorrhaged 
animals. 
Sham rats were excluded when comparing animals that survived to 10 days 
after 60% blood loss and those that did not because, since shams were not 
hemorrhaged and they all lived to 10 days, they could skew the results. MAP, HR, 
and rectal temperature were higher at T90 in animals that lived to 10 days (p<0.05). 
HR was also higher at T105 (p<0.05) in 10-day survivors. 
Shams were not included in out Cox Proportional Hazards regression 
analyses also. At T90, lower MAP (p<0.01; HR=0.97), HR (p<0.05; HR=0.99), and 
rectal temperature (p<0.05; HR=.49) resulted in lower survival. Higher rectal 
temperature (p<0.05; HR=2.29) at T20 lead to a decrease in survival. 
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Table 3.5. Melatonin Dose-Ranging Study II: Physiological constant data. 
 
Statistical significance is denoted by the presence of different letters. Groups not sharing a letter are statistically different (p<0.05). Abbreviations: 
Mel-Melatonin. 
Sham 99.20 ± 12.00 A 84.77 ± 12.57 A 84.77 ± 12.57 A 84.29 ± 11.70 A 97.45 ± 13.33 A 96.18 ± 12.66 AB
4.3 mM Mel 97.31 ± 6.15 A 25.97 ± 0.96 B 58.84 ± 14.20 B 25.48 ± 2.79 B 76.28 ± 17.66 AB 108.71 ± 17.23 AB
0.43 mM Mel 102.56 ± 10.91 A 24.59 ± 0.88 B 62.22 ± 11.77 B 25.10 ± 4.67 B 79.39 ± 8.39 AB 114.86 ± 10.57 A
0.0043 mM Mel 92.15 ± 8.60 A 24.08 ± 1.56 B 44.30 ± 11.26 C 20.89 ± 3.81 B 60.49 ± 20.53 B 92.86 ± 17.61 B
0.000043 mM Mel 100.62 ± 10.62 A 25.57 ± 1.78 B 49.28 ± 9.84 BC 24.07 ± 6.60 B 64.35 ± 23.16 B 97.07 ± 9.86 AB
0 mM Mel 97.92 ± 5.76 A 25.75 ± 0.99 B 53.74 ± 7.78 BC 24.86 ± 2.70 B 80.06 ± 16.95 AB 113.65 ± 9.35 A
NaCl Control 95.21 ±3.65 A 25.90 ± 2.27 B 53.29 ± 7.55 BC 22.91 ± 3.17 B 70.60 ± 19.50 B 111.06 ± 21.17 AB
Sham 367.09 ± 46.53 A 348.23 ± 58.20 A 338.40 ± 52.39 A 321.71 ± 54.76 A 303.60 ± 23.39 A 295.79 ± 26.31 A
4.3 mM Mel 354.19 ± 34.16 A 213.71 ± 46.85 B 256.07 ± 48.12 B 215.24 ± 52.11 B 278.12 ± 29.04 AB 258.46 ± 24.13 AB
0.43 mM Mel 377.49 ± 57.74 A 193.78 ± 44.04 B 255.21 ± 35.59 B 215.07 ± 28.74 B 260.44 ± 23.45 AB 251.39 ± 24.88 B
0.0043 mM Mel 364.37 ± 36.37 A 217.33 ± 36.05 B 219.63 ± 34.44 B 229.02 ± 64.67 B 241.31 ± 52.85 B 221.89 ± 51.64 B
0.000043 mM Mel 363.69 ± 23.42 A 210.02 ± 17.45 B 220.20 ± 19.06 B 227.77 ± 57.98 B 254.37 ± 45.95 AB 229.09 ± 28.01 B
0 mM Mel 366.59 ± 48.82 A 214.83 ± 72.93 B 240.45 ± 32.60 B 225.22 ± 29.28 B 271.36 ± 35.08 AB 251.02 ± 23.16 B
NaCl Control 342.91 ± 26.68 A 195.29 ± 31.76 B 215.62 ± 23.80 B 201.76 ± 29.35 B 244.42 ± 31.59 B 230.66 ± 27.16 B
Sham 35.52 ± 0.37 A 33.83 ± 0.48 A 32.86 ± 0.67 A 32.06 ± 0.65 A 29.35 ± 0.56 A 29.03 ± 0.54 A
4.3 mM Mel 35.05 ± 0.66 A 33.27 ± 0.83 A 31.75 ± 0.82 AB 31.26 ± 0.86 AB 27.27 ± 1.33 AB 27.11 ± 1.07 B
0.43 mM Mel 35.13 ± 0.49 A 32.90 ± 0.88 A 31.36 ± 1.04 B 30.79 ± 1.12 AB 26.55 ± 1.56 B 26.46 ± 1.28 B
0.0043 mM Mel 34.92 ± 0.65 A 32.92 ± 0.72 A 31.16 ± 0.83 B 30.41 ± 0.88 B 25.67 ± 1.11 B 25.50 ± 1.26 B
0.000043 mM Mel 35.74 ± 0.70 A 33.45 ± 0.95 A 31.78 ± 1.27 AB 30.99 ± 1.28 AB 26.73 ± 2.39 B 26.81 ± 1.34 B
0 mM Mel 35.15 ± 0.48 A 32.96 ± 1.22 A 31.47 ± 1.29 B 30.81 ± 1.59 AB 26.75 ± 2.18 B 26.46 ± 2.04 B
NaCl Control 35.42 ± 0.64 A 33.16 ± 0.69 A 31.32 ± 0.87 B 30.59 ± 1.14 B 26.21 ± 1.56 B 25.84 ± 1.65 B
MAP (mmHg)
T0 T10 T20 T30 T90 T105
Mean ± SD
HR (BPM)
T0 T10 T20 T30 T90 T105
Mean ± SD
Rectal Temperature (°C)
T0 T10 T20 T30 T90 T105
Mean ± SD
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T1AM Pilot Study 
3-iodothyronamine (T1AM) has been shown to induce non-shivering 
hypothermia in mice (Scanlan, Suchland et al. 2004). For that reason, we 
hypothesized that T1AM, in combination with the optimized BHB/M can induce a 
hibernation-like protective state that improves recovery from normally lethal 
hemorrhagic shock. 
Initially, we decided to investigate whether the observations made by 
Scanlan et al (2004) could be replicated in a rat model. Therefore, we conducted a 
pilot study to determine whether T1AM could induce hypothermia in normotensive 
animals subjected to the instrumentation procedures common to our hemorrhagic 
shock model. None of these animals were hemorrhaged. The treatments included a 
semi-log dose range from 0 to 50 mg/kg in 10 rats (n=2 per treatment). Though a 
reduction in temperature was observed, there were no observable differences 
between treatments (Figure 3.9). It is possible that the anesthesia could be masking 
the thyroid hormone derivative. It has been described that mice injected with T1AM 
take 6 to 8 hours to return to normal behavior (Scanlan, Suchland et al. 2004). 
However, we observed that rats recovered as soon as the anesthesia wore off (~10 
minutes). 
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Figure 3.9. T1AM Pilot Study: Rectal temperature data. 
Infusion of either 50 mg/kg T1AM (n=2), 25 mg/kg T1AM (n=2), 10 mg/kg T1AM (n=2), 2 mg/kg 
T1AM (n=2), or 0 mg/kg T1AM (n=2) was achieved by administering a single 1 ml/kg bolus. Times 
on the x-axis reflect minutes. Data points are depicted as mean ± SEM. 
Whole-Blood Parameters 
If the mean survival was not different between hemorrhaged groups for a 
specific experiment, whole-blood parameters for that experiment will not be 
detailed. 
Optimization of Composition 
BHB Dose-Ranging Study 
All treatment differences are summarized in Table 3.6 and Figure 3.10. 
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Acidosis is considered a good indicator of decreased oxygen delivery during 
the early stages of hemorrhagic shock. A pH of 7.30-7.35 is considered tolerable 
whereas a pH of ≤ 7.2 is considered life-threatening (Blalock 1940). Treatments 
differences in pH were observed at T0. This is more reflective of individual 
variation since all animals have been instrumented as per the protocol in the 
methods section and no infusion has taken place at this time point. All groups 
presented reductions in pH, this could be in part as a result in rectal temperature 
drops, even though results were temperature-corrected. The 4 M BHB and 2 M 
BHB treatments had lower pH than shams at T30 (p<0.05). However, the 
differences were only 0.04 and 0.15 points, respectively. 
tHb decreases as a result of blood loss and fluid replacement (Gutierrez, 
Reines et al. 2004). Statistical differences in tHb were not observed until T30 
between sham-operated animals and all hemorrhaged groups (p<0.0001) as the loss 
of blood is accompanied by a reduction in red cell mass (Carey, Lowery et al. 1971). 
A blood transfusion restored tHb levels close to baseline in hypovolemic animals. 
sO2 is a measure of oxygenation. It can be used to assess hypoxemia and 
imbalances in oxygen delivery (Cheatham, Block et al. 2008). sO2 at T0 was 
slightly decreased in all groups, probably as a result of anesthesia as isoflurane has 
been known to cause dips in sO2 at concentrations larger than 2% (Palahniuk and 
Shnider 1974). 
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pO2 is an indicator of perfusion, or the oxygen delivery capacity of the lungs 
(Guyton and Hall 2001). pO2 was higher in all hemorrhaged treatments compared 
to shams at T20 (p<0.0001), T30 (p<0.01), T30 (p<0.0001), T90 (p<0.0001), and 
T105 (p<0.001). This is contrary to the expectation that pO2 will be depressed in 
shocked animals (Carey, Lowery et al. 1971). However, it reflects intact respiratory 
function. 
pCO2 represents ventilation and denotes air exchange in the lungs and CO2 
elimination (Guyton and Hall 2001). Changes in pCO2, though minimal and not 
statistically different between treatments (p>0.05), seemed to parallel changes in 
blood pressure. 
Hyperkalemia is expected to occur in sever shock. The Na-K pump requires 
ATP in order to function properly. As ATP levels decrease during ischemia, the 
cells lose their ability to maintain chemical differences between intracellular and 
extracellular fluids causing an increase in extracellular K+ (Carey, Lowery et al. 
1971). In rats subjected to hypovolemia, circulating K+ levels increased as the 
hemorrhagic phase progressed but returned to levels close to baseline during the 
shock period. In contrast, blood K+ in shams was lower from T0 to T10 but 
continually increased, resulting in statistically higher levels (p<0.05) when 
compared to all hemorrhaged groups at the end of the surgical procedure. However, 
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mean K+ concentrations were not outside of the normal range (3.9-9.2 mmol/L) 
(Sharp and Villano 1998) at any time point in any group. 
Na-K pump dysfunction also results in an increase of intracellular Na+, 
therefore hemorrhage lowers blood Na+ levels (Carey, Lowery et al. 1971). Since 
the BHB we used comes in its sodium salt form, circulating Na+ increased upon 
infusion. The one-hour shock period allowed Na+ to go back to homeostatic values. 
In shams, blood Na+ increased after the first few blood samples and then slowly 
returned to its basal range. 
A 
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Figure 3.10. BHB Dose-Ranging Study: Whole-blood parameter data. 
Infusion of either 4 M BHB (n=6), 2 M BHB (n=5), or 0.4 M BHB (n=5) was achieved by 
administering a single 1 ml/kg bolus. All solutions contained 4.3 mM melatonin and 10% DMSO. 
Times on the x-axis reflect minutes. Data points are depicted as mean ± SEM. 
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Table 3.6. BHB Dose-Ranging Study: Whole-blood parameter data. 
 
Sham 13.02 ± 0.78 A 12.17 ± 0.95 A 12.24 ± 0.77 A 11.83 ± 0.86 A 11.69 ± 1.54 A 8.35 ± 5.28 A
4 M BHB 13.47 ± 0.45 A 10.65 ± 1.24 A 8.70 ± 0.20 BC 9.30 ± 0.36 B 9.30 ± 1.25 B 11.33 ± 0.97 A
2 M BHB 13.34 ± 0.60 A 9.30 ± 4.21 A 9.30 ± 0.75 BC 8.84 ± 1.41 B 9.50 ± 1.07 B 11.55 ± 1.02 A
0.4 M BHB 13.13 ± 1.09 A 11.52 ± 0.46 A 9.78 ± 0.86 B 10.26 ± 0.89 B 10.63 ± 0.32 AB 10.95 ± 0.21 A
Sham 7.4 ± 0.04 A 7.38 ± 0.08 A 7.38 ± 0.06 A 7.33 ± 0.16 A 7.27 ± 0.19 A 7.27 ± 0.14 A
4 M BHB 7.30 ± 0.08 B 7.30 ± 0.13 A 7.23 ± 0.08 B 7.29 ± 0.10 A 7.16 ± 0.09 A 7.13 ± 0.16 A
2 M BHB 7.27 ± 0.07 B 7.24 ± 0.16 A 7.17 ± 0.19 B 7.18 ± 0.20 A 7.09 ± 0.14 A 7.08 ± 0.09 A
0.4 M BHB 7.29 ± 0.08 B 7.35 ± 0.08 A 7.25 ± 0.11 AB 7.27 ± 0.11 A 7.05 ± 0.15 A 7.07 ± 0.08 A
Sham 96.15 ± 2.80 A 95.99 ± 1.46 A 92.14 ± 4.21 A 94.90 ± 4.04 A 95.66 ± 2.59 A 96.51 ± 0.70 A
4 M BHB 90.66 ± 5.10 A 96.01 ± 1.35 A 95.23 ± 1.16 A 96.28 ± 0.98 A 95.92 ± 1.21 A 94.02 ± 1.62 A
2 M BHB 90.12 ± 6.40 A 95.80 ± 2.17 A 95.38 ± 2.66 A 95.76 ± 1.94 A 96.60 ± 1.51 A 94.30 ± 0.41 A
0.4 M BHB 91.58 ± 4.34 A 96.72 ± 0.40 A 96.02 ± 1.29 A 95.88 ± 0.59 A 95.95 ± 2.62 A 95.20 ± 2.12 A
Sham 81.41 ± 10.83 A 75.62 ± 8.32 B 78.30 ± 13.86 B 72.30 ± 14.85 B 61.76 ± 15.28 B 72.73 ± 26.69 B
4 M BHB 92.3 ± 0.57 A 127.75 ± 8.18 A 126.50 ± 0.71 A 136.00 ± 5.29 A 148.50 ± 17.91 A 137.67 ± 4.97 A
2 M BHB 94.10 ± 14.54 A 123.00 ± 3.61 A 128.67 ± 5.35 A 142.00 ± 1.41 A 153.60 ± 17.26 A 150.20 ± 19.59 A
0.4 M BHB 92.56 ± 8.25 A 128.33 ± 8.12 A 132.75 ± 3.20 A 139.00 ± 8.49 A 140.45 ± 31.79 A 150.00 ± 6.25 A
T105
tHb (g/dL)
pH
sO2 (%)
pO2 (mmHg)
T105
T0 T10 T20
Mean ± SD
Mean ± SD
Mean ± SD
Mean ± SD
T30 T90
T0 T10 T20 T30 T90
T30 T90 T105
T0 T10 T20 T30 T90 T105
T0 T10 T20
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Sham 41.1 ± 5.62 A 37.84 ± 4.73 A 39.37 ± 4.63 A 38.39 ± 6.86 A 41.18 ± 6.85 A 31.94 ± 13.56 A
4 M BHB 43.34 ± 6.98 A 36.38 ± 4.45 A 38.87 ± 8.00 A 36.01 ± 4.41 A 40.65 ± 8.18 A 52.93 ± 4.92 A
2 M BHB 45.83 ± 4.70 A 36.94 ± 6.66 A 39.55 ± 7.13 A 33.38 ± 3.24 A 40.95 ± 0.75 A 51.24 ± 6.10 A
0.4 M BHB 49.53 ± 6.75 A 35.32 ± 8.16 A 41.71 ± 3.88 A 32.23 ± 2.18 A 40.97 ± 3.97 A 45.55 ± 5.45 A
Sham 4.02 ± 0.26 A 3.57 ± 0.33 B 3.56 ± 0.25 B 3.75 ± 0.42 B 4.26 ± 0.50 A 4.44 ± 0.52 A
4 M BHB 3.76 ± 0.37 A 4.17 ± 0.24 A 4.28 ± 0.50 A 4.34 ± 0.49 B 3.20 ± 0.53 B 3.10 ± 0.28 B
2 M BHB 4.05 ± 0.22 A 4.40 ± 0.12 A 4.30 ± 0.58 A 5.42 ± 0.58 A 3.64 ± 0.67 AB 3.54 ± 0.48 B
0.4 M BHB 3.70 ± 0.24 A 4.32 ± 0.32 A 4.73 ± 0.38 A 5.32 ± 1.02 A 4.20 ± 1.14 AB 3.43 ± 0.38 B
Sham 139.40 ± 1.65 A 142.36 ± 2.25 A 142.50 ± 1.96 A 142.36 ± 3.23 A 140.55 ± 2.95 A 137.63 ± 4.31 A
4 M BHB 136.71 ± 1.25 B 136.43 ± 3.05 B 139.83 ± 2.40 A 135.71 ± 1.11 BC 142.71 ± 5.82 A 141.17 ± 2.64 A
2 M BHB 138.33 ± 2.16 AB 137.80 ± 2.59 B 139.17 ± 2.14 A 134.80 ± 2.05 C 138.40 ± 2.07 A 139.20 ± 3.03 A
0.4 M BHB 139.50 ± 1.38 A 137.83 ± 1.33 B 137.67 ± 1.75 A 134.8 ± 2.39 C 139.75 ± 1.71 A 139.67 ± 4.51 A
Sham 1.40 ±0.03 AB 1.33 ± 0.06 C 1.36 ± 0.03 AB 1.36 ± 0.07 BC 1.43 ± 0.07 A 1.39 ± 0.06 A
4 M BHB 1.33 ± 0.05 B 1.36 ± 0.07 BC 1.25 ± 0.07 BC 1.31 ± 0.05 C 1.30 ± 0.08 B 1.36 ± 0.13 A
2 M BHB 1.41 ± 0.08 AB 1.45 ± 0.08 AB 1.34 ± 0.11 AB 1.4 ± 0.09 AB 1.40 ± 0.10 AB 1.37 ± 0.09 A
0.4 M BHB 1.43 ± 0.03 A 1.48 ± 0.02 A 1.41 ± 0.03 A 1.48 ± 0.04 A 1.48 ± 0.05 A 1.38 ± 0.06 A
pCO2 (mmHg)
Ca++ (mmol/L)
K+ (mmol/L)
Mean ± SD
Mean ± SD
Mean ± SD
Mean ± SD
T105T0 T10 T20 T30 T90
T105
T0 T10 T20 T30 T90 T105
Na+ (mmol/L)
T0 T10 T20 T30 T90
T0 T10 T20 T30 T90 T105
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Statistical significance is denoted by the presence of different letters. Groups not sharing a letter are statistically different (p<0.05). Abbreviations: 
BHB-β-Hydroxybutyrate. 
 
 
Sham 109.00 ± 7.83 A 110.91 ± 6.04 A 109.50 ± 2.76 A 112.18 ± 7.29 A 114.36 ± 5.78 A 118.89 ± 10.62 A
4 M BHB 108.71 ± 13.49 A 108.57 ±10.57 A 104.50 ± 4.23 A 105.57 ± 11.15 A 108.71 ± 12.83 A 112.17 ± 13.83 A
2 M BHB 111.17 ± 13.79 A 106.60 ± 2.30 A 111.83 ± 8.06 A 106.80 ± 3.90 A 113.40 ± 14.15 A 112.80 ± 9.04 A
0.4 M BHB 107.67 ± 5.57 A 110.17 ± 9.30 A 111.83 ± 9.00 A 107.40 ± 2.07 A 115.50 ± 13.10 A 117.00 ± 10.39 A
Sham 263.10 ± 23.85 A 234.36 ± 32.41 B 240.20 ± 35.12 B 249.18 ± 56.80 B 264.46 ± 59.72 B 224.00 ± 123.63 B
4 M BHB 250.57 ± 30.20 A 294.43 ± 24.23 A 348.00 ± 78.50 A 388.86 ± 69.53 A 428.57 ± 92.99 A 434.83 ± 110.41 A
2 M BHB 289.33 ± 21.77 A 306.00 ± 41.73 A 350.33 ± 103.14 A 439.00 ± 59.55 A 505.60 ± 126.29 A 451.80 ± 127.70 A
0.4 M BHB 283.33 ± 36.43 A 320.67 ± 43.88 A 434.83 ± 39.09 A 476.20 ± 28.62 A 529.00 ± 72.80 A 504.67 ± 86.52 A
Sham 9.50 ± 4.06 A 9.70 ± 3.92 B 9.40 ± 3.20 B 8.82 ± 2.52 B 7.30 ± 1.26 B 5.86 ± 4.38 B
4 M BHB 8.00 ± 1.83 A 27.43 ± 13.24 A 48.67 ± 15.68 A 48.57 ± 14.14 A 51.57 ± 16.39 A 52.50 ± 21.04 A
2 M BHB 9.67 ± 4.46 A 22.20 ± 4.60 A 45.33 ± 23.30 A 57.80 ± 10.73 A 62.00 ± 24.11 A 49.80 ± 32.27 A
0.4 M BHB 10.33 ± 4.18 A 26.33 ± 5.92 A 50.67 ± 9.25 A 63.80 ± 9.86 A 66.75 ± 41.06 A 47.33 ± 22.50 AB
Mean ± SD
Cl- (mmol/L)
Glu (mg/dL)
Mean ± SD
T105T0 T10 T20 T30 T90
T105
T0 T10 T20 T30 T90 T105
Mean ± SD
T0 T10 T20 T30 T90
Lac (mg/dL)
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A slight hypocalcemia can be expected as a result of hemorrhagic shock and 
ischemia/reperfusion injury as there is a rapid intracellular Ca++ influx as there is a 
disruption in Ca++ channel activity (Carey, Lowery et al. 1971). Ca++ blood 
concentrations varied between groups enough to show statistical differences at T0 
(p<0.05). However, this is just reflective of individual variation between the 
animals assigned to each group and the Ca++ levels were not outside of the reference 
values (1.2-1.6 mmol/L) (Sharp and Villano 1998). With blood withdrawal, 
circulating Ca++ increased but they decreased upon infusion. In fact, Ca++ levels 
somewhat mirrored the curves for Na+ and MAP. Nonetheless, these fluctuations 
remained within the normal value range. 
Hypochloremia may occur in hemorrhagic shock as cellular membrane 
dysfuction results in an intracellular uptake of Cl- (Carey, Lowery et al. 
1971).Circulating Cl- levels fluctuated without a specific pattern or trend but tended 
towards the higher end of the reference levels (84-110 mmol/L) (Sharp and Villano 
1998). 
Gluconeogeneiss is increased early during shock as a response to increased 
catecholamine (e.g. adrenalin) release. Also, the shift from aerobic to anaerobic 
metabolism results in an increase in lactate production (Carey, Lowery et al. 1971). 
Sham-operated animals had lower Glu and Lac levels than all other treatments 
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(p<0.05) at all time points except T0, consistent with a normal response to shock 
(Carey, Lowery et al. 1971). 
Melatonin Dose-Ranging Study II 
Differences between treatments are shown in Table 3.7 and Figure 3.11. 
When it comes to tHb, all groups were indistinguishable at T0. tHb was 
consistently higher in shams compared to hemorrhaged animals. Those differences 
were no longer present after a blood transfusion. 
pO2 was consistently lower in shams compared to all other treatments 
except at T0 and T105. The opposite was observed with pCO2. 
K+ levels in the hemorrhaged groups seemed to mirror MAP. In the sham 
group, circulating K+ decreased initially and then gradually increased. 
A 
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Figure 3.11. Melatonin Dose-Ranging Study II: Whole-blood parameter data. 
Infusion of either 4.3 mM melatonin (n=10), 0.43 mM melatonin (n=10), 0.0043 mM 
melatonin (n=10), 0.000043 mM melatonin (n=10), or 0 mM melatonin (n=10) was achieved by 
administering a single 1 ml/kg bolus. All solutions contained 4 M BHB and 2% DMSO. A control 
group was also included and they were administered 4 M NaCl with 0.000043 mM melatonin in 2% 
DMSO (n=10). Times on the x-axis reflect minutes. Data points are depicted as mean ± SEM. 
In hemorrhaged animals, blood Na+ decreased with blood withdrawals and 
increased with treatment infusion. Over the one-hour shock period, circulating Na+ 
increased slightly. In sham animals, Na+ levels stayed relatively constant. 
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Blood Ca++ concentrations varied and seemed to somewhat mirror MAP. 
However, those changes never fluctuated beyond the reference values for Ca++. 
Cl- was higher in the animals infused with the NaCl control treatment from 
T20 onwards. 
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Table 3.7. Melatonin Dose-Ranging Study II: Whole-blood parameter data. 
 
T0 T10 T20 T30 T90 T105
Sham 13.02 ± 0.78 A 12.17 ± 0.95 A 12.24 ± 0.77 A 11.83 ± 0.86 A 11.69 ± 1.54 A 8.35 ± 5.28 A
4.3 mM Mel 12.60 ± 0.92 A 10.91 ± 1.58 B 8.67 ± 0.76 B 8.61 ± 0.53 B 9.16 ± 1.55 B 10.30 ± 0.59 A
0.43 mM Mel 12.90 ± 0.80 A 10.30 ± 0.82 B 8.59 ± 0.51 B 8.76 ± 0.61 B 8.50 ± 0.63 B 10.31 ± 0.91 A
0.0043 mM Mel 12.74 ± 0.81 A 10.72 ± 0.75 B 8.55 ± 0.32 B 8.89 ± 0.46 B 8.78 ± 0.45 B 10.90 ± 0.84 A
0.000043 mM Mel 13.30 ± 0.65 A 11.29 ± 0.69 AB 8.73 ± 0.38 B 9.17 ± 0.51 B 9.11 ± 0.28 B 9.85 ± 2.26 A
0 mM Mel 12.49 ± 0.70 A 10.89 ± 0.44 B 8.28 ± 0.46 B 8.76 ± 0.33 B 8.53 ± 1.16 B 10.38 ± 0.92 A
NaCl Control 13.61 ± 0.59 A 11.29 ± 0.36 AB 8.63 ± 1.40 B 9.36 ± 0.40 B 9.16 ± 1.18 B 11.18 ± 0.56 A
T0 T10 T20 T30 T90 T105
Sham 7.40 ± 0.04 A 7.38 ± 0.08 A 7.38 ± 0.06 A 7.33 ± 0.20 A 7.27 ± 0.19 A 7.27 ± 0.14 A
4.3 mM Mel 7.41 ± 0.06 A 7.37 ± 0.21 A 7.31 ± 0.22 A 7.39 ± 0.17 A 7.32 ± 0.11 A 7.23 ± 0.19 A
0.43 mM Mel 7.43 ± 0.03 A 7.49 ± 0.06 A 7.40 ± 0.08 A 7.46 ±0.06 A 7.40 ± 0.07 A 7.31 ± 0.15 A
0.0043 mM Mel 7.372 ± 0.05 A 7.43 ± 0.07 A 7.33 ± 0.09 A 7.43 ± 0.12 A 7.32 ± 0.08 A 7.24 ± 0.12 A
0.000043 mM Mel 7.41 ± 0.04 A 7.40 ± 0.12 A 7.31 ± 0.13 A 7.39 ± 0.14 A 7.34 ± 0.08 A 7.26 ± 0.06 A
0 mM Mel 7.42 ± 0.07 A 7.50 ± 0.05 A 7.40 ± 0.06 A 7.46 ± 0.04 A 7.35 ± 0.10 A 7.29 ± 0.10 A
NaCl Control 7.41 ± 0.05 A 7.46 ± 0.07 A 7.33 ± 0.09 A 7.40 ± 0.12 A 7.32 ± 0.09 A 7.26 ± 0.13 A
T0 T10 T20 T30 T90 T105
Sham 96.15 ± 2.79 A 96.00 ± 1.46 A 92.14 ± 4.21 BC 94.90 ± 4.04 A 95.66 ± 2.59 A 96.51 ± 0.70 A
4.3 mM Mel 92.14 ± 3.53 AB 96.66 ± 0.91 A 96.23 ± 1.56 AB 96.53 ± 1.07 A 96.71 ± 0.96 A 92.33 ± 5.14 A
0.43 mM Mel 93.04 ± 3.60 AB 96.41 ± 1.05 A 95.19 ± 0.99 AB 96.36 ± 0.43 A 96.92 ± 1.08 A 95.00 ± 2.16 A
0.0043 mM Mel 88.86 ± 7.34 B 96.54 ± 0.74 A 94.94 ± 1.69 AB 95.87 ± 2.45 A 96.06 ± 0.84 A 92.05 ± 8.94 A
0.000043 mM Mel 95.19 ± 3.44 A 93.69 ± 2.06 A 96.24 ± 0.86 A 93.27 ± 3.47 A 95.53 ± 1.32 A 95.84 ± 1.83 A
0 mM Mel 92.88 ± 2.20 AB 96.81 ± 1.19 A 96.28 ± 1.20 A 97.06 ± 0.92 A 97.00 ± 1.25 A 93.07 ± 5.72 A
NaCl Control 94.47 ± 4.06 AB 87.82 ± 16.11 A 90.00 ± 4.81 C 95.56 ± 1.53 A 95.62 ± 1.80 A 94.87 ± 3.13 A
tHb (g/dL)
pH
sO2 (%)
Mean ± SD
Mean ± SD
Mean ± SD
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T0 T10 T20 T30 T90 T105
Sham 81.41 ± 10.83 A 75.62 ± 8.32 B 78.30 ± 13.86 A 72.30 ± 14.85 B 61.76 ± 15.28 B 72.73 ± 26.69 A
4.3 mM Mel 79.36 ± 11.92 A 105.84 ± 12.83 A 95.62 ± 8.54 A 109.00 ± 3.27 A 112.03 ± 11.21 A 80.08 ± 27.00 A
0.43 mM Mel 85.03 ± 14.36 A 104.64 ± 6.71 A 97.85 ± 8.70 A 97.60 ± 6.73 AB 111.10 ± 7.30 A 84.61 ± 20.69 A
0.0043 mM Mel 72.02 ± 4.34 A 101.07 ± 6.83 A 90.88 ± 6.60 A 110.75 ± 10.62 A 116.33 ± 16.71 A 96.50 ± 33.40 A
0.000043 mM Mel 82.25 ± 9.68 A 98.07 ± 9.90 A 105.73 ± 14.34 A 107.90 ± 14.66 A 115.90 ± 21.23 A 73.70 ± 26.66 A
0 mM Mel 81.01 ± 12.77 A 104.70 ± 9.00 A 104.63 ± 11.33 A 111.60 ± 2.07 A 124.33 ± 26.65 A 92.29 ± 16.95 A
NaCl Control 67.78 ± 15.28 A 94.82 ± 13.21 A 95.78 ± 6.74 A 117.60 ± 21.84 A 116.20 ± 21.47 A 86.13 ± 15.78 A
T0 T10 T20 T30 T90 T105
Sham 41.10 ± 5.62 AB 37.84 ± 4.73 A 39.37 ± 4.63 A 38.39 ± 6.86 A 41.18 ± 6.85 A 31.94 ± 13.56 A
4.3 mM Mel 38.21 ± 7.90 AB 29.90 ± 4.73 B 31.25 ± 4.82 BC 26.94 ± 5.90 B 27.62 ± 6.62 B 33.29 ± 4.90 A
0.43 mM Mel 40.48 ± 4.64 AB 27.65 ± 3.31 B 29.74 ± 2.47 BC 24.43 ± 1.23 B 24.33 ± 2.32 B 29.84 ± 4.11 A
0.0043 mM Mel 46.21 ± 5.47 A 32.45 ± 5.12 AB 33.51 ± 3.75 AB 24.93 ± 5.70 B 23.89 ± 6.38 B 30.92 ± 4.98 A
0.000043 mM Mel 41.93 ± 3.29 AB 29.95 ± 2.50 B 28.56 ± 4.61 BC 23.84 ± 6.20 B 24.36 ± 8.48 B 32.56 ± 9.37 A
0 mM Mel 36.01 ± 7.15 B 26.95 ± 4.62 B 25.53 ± 4.15 C 22.27 ± 3.51 B 21.50 ± 4.69 B 26.34 ± 4.03 A
NaCl Control 46.55 ± 8.22 A 33.92 ± 7.90 AB 32.02 ± 5.92 B 27.31 ± 4.70 B 25.00 ± 4.24 B 29.04 ± 10.20 A
T0 T10 T20 T30 T90 T105
Sham 4.02 ± 0.26 AB 3.57 ± 0.33 B 3.56 ± 0.25 B 3.75 ± 0.42 C 4.26 ± 0.50 A 4.44 ± 0.52 A
4.3 mM Mel 3.88 ± 0.31 AB 4.36 ± 0.44 A 3.92 ± 0.61 AB 4.16 ± 0.58 BC 3.40 ± 0.57 BC 3.37 ± 0.48 BC
0.43 mM Mel 3.93 ± 0.33 AB 4.20 ±.018 A 3.86 ± 0.45 AB 3.99 ± 0.45 BC 3.10 ± 0.32 C 3.16 ± 0.22 C
0.0043 mM Mel 4.19 ± 0.27 A 4.54 ± 0.25 A 4.43 ± 0.45 A 4.91 ± 0.69 A 3.82 ±0.57 AB 3.76 ± 0.58 B
0.000043 mM Mel 3.98 ± 0.23 AB 4.31 ± 0.28 A 4.00 ± 0.16 AB 4.25 ± 0.28 ABC 3.40 ± 0.64 BC 3.30 ±0.16 BC
0 mM Mel 4.06 ± 0.35 AB 4.26 ± 0.21 A 4.13 ± 0.62 AB 4.41 ± 0.38 ABC 3.19 ± 0.40 BC 3.15 ± 0.30 C
NaCl Control 3.71 ± 0.29 B 4.23 ± 0.29 A 4.25 ± 0.40 A 4.62 ± 0.56 AB 3.63 ± 0.42 ABC 3.53 ± 0.39 BC
pO2 (mmHg)
pCO2 (mmHg)
K+ (mmol/L)
Mean ± SD
Mean ± SD
Mean ± SD
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T0 T10 T20 T30 T90 T105
Sham 139.40 ±1.65 ABC 142.36 ± 2.25 A 142.50 ±1.96 AB 142.36 ± 3.23 A 140.55 ± 2.95 A 137.63 ± 4.31 B
4.3 mM Mel 141.89 ± 2.62 A 140.14 ± 4.71 AB 146.50 ± 1.87 A 141.88 ± 2.30 AB 144.33 ± 4.50 A 143.86 ± 5.76 AB
0.43 mM Mel 137.44 ± 2.01 BC 135.00 ± 1.31 D 139.33 ± 2.35 B 136.25 ± 2.66 C 140.67 ± 3.84 A 140.67 ± 4.24 AB
0.0043 mM Mel 140.22 ± 1.79 AB 138.20 ± 1.69 BCD 143.20 ± 2.10 AB 138.82 ± 1.89 ABC 142.33 ± 5.00 A 141.82 ± 3.97 AB
0.000043 mM Mel 140.38 ± 2.39 AB 139.13 ± 3.23 ABC 145.38 ± 4.69 A 140.63 ± 4.44 AB 146.88 ± 7.30 A 145.80 ± 2.78 A
0 mM Mel 139.70 ± 2.54 ABC 138.00 ± 2.39 BCD 142.40 ± 3.78 AB 138.44 ± 2.79 BC 140.89 ± 4.76 A 142.33 ± 3.87 AB
NaCl Control 137.00 ± 1.33 C 135.70 ± 1.16 CD 143.30 ± 2.16 AB 137.78 ± 0.97 BC 141.11 ± 4.11 A 140.80 ± 4.19 AB
T0 T10 T20 T30 T90 T105
Sham 1.40 ± 0.03 AB 1.33 ± 0.06 B 1.35 ± 0.03 A 1.36 ±0.07 AB 1.43 ± 0.07 A 1.39 ± 0.06 A
4.3 mM Mel 1.43 ± 0.13 AB 1.47 ± 0.17 A 1.31 ± 0.05 ABC 1.41 ± 0.10 AB 1.36 ± 0.11 A 1.34 ± 0.07 A
0.43 mM Mel 1.37 ± 0.04 AB 1.39 ± 0.04 AB 1.23 ± 0.05 C 1.33 ± 0.02 B 1.34 ± 0.09 A 1.32 ± 0.07 A
0.0043 mM Mel 1.44 ± 0.05 A 1.47 ± 0.03 A 1.32 ± 0.07 AB 1.42 ± 0.06 A 1.36 ± 0.07 A 1.38 ± 0.05 A
0.000043 mM Mel 1.44 ± 0.06 A 1.49 ± 0.09 A 1.26 ± 0.07 BC 1.38 ± 0.10 AB 1.34 ± 0.10 A 1.37 ± 0.07 A
0 mM Mel 1.44 ± 0.06\ A 1.46 ± 0.06 A 1.27 ± 0.05 BC 1.37 ± 0.04 AB 1.36 ± 0.11 A 1.37 ± 0.06 A
NaCl Control 1.35 ± 0.03 B 1.41 ± 0.03 AB 1.32 ± 0.05 AB 1.43 ± 0.03 A 1.39 ± 0.04 A 1.37 ± 0.09 A
T0 T10 T20 T30 T90 T105
Sham 109 ± 7.83 AB 110.91 ± 6.04 A 109.50 ± 2.76 B 112.18 ± 7.29 A 114.36 ± 5.78 AB 118.88 ± 10.62 A
4.3 mM Mel 106.11 ± 2.37 AB 107.83 ± 0.75 ABC 107.00 ± 2.68 B 104.88 ± 2.90 B 107.11 ± 2.37 C 108.71 ± 1.80 ABC
0.43 mM Mel 105.22 ± 3.87 AB 106.13 ± 3.31 BC 104.71 ± 3.30 B 102.75 ± 4.06 B 104.43 ± 2.94 C 106.14 ± 6.10 C
0.0043 mM Mel 104.67 ± 3.00 AB 105.00 ± 1.94 C 105.80 ± 2.86 B 103.36 ± 3.56 B 106.89 ± 5.13 C 107.73 ± 7.46 C
0.000043 mM Mel 106.00 ± 2.20 AB 106.25 ± 2.87 ABC 110.00 ± 8.42 B 107.13 ± 8.48 AB 110.38 ± 5.78 BC 113.80 ± 8.90 ABC
0 mM Mel 104.50 ± 2.22 B 106.88 ± 2.23 ABC 106.70 ± 3.23 B 104.22 ± 2.82 B 105.63 ± 3.78 C 107.89 ± 2.76 BC
NaCl Control 110.10 ± 1.45 A 110.30 ± 1.16 AB 119.00 ± 2.91 A 113.70 ± 2.54 A 120.00 ± 8.02 A 116.89 ± 3.76 AB
Mean ± SD
Mean ± SD
Mean ± SD
Na+ (mmol/L)
Ca++ (mmol/L)
Cl- (mmol/L)
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Statistical significance is denoted by the presence of different letters. Groups not sharing a letter are statistically different (p<0.05). Abbreviations: 
Mel-Melatonin.
T0 T10 T20 T30 T90 T105
Sham 263.10 ± 23.85 A 234.36 ± 32.41 C 240.20 ± 35.12 C 249.18 ± 56.80 D 264.46 ± 59.72 C 224.00 ± 123.63 B
4.3 mM Mel 266.45 ± 21.75 A 305.00 ± 29.16 AB 353.33 ± 25.89 AB 416.50 ± 28.54 ABC 544.38 ± 80.00 A 484.86 ± 82.33 A
0.43 mM Mel 237.56 ± 34.67 A 287.75 ± 40.62 AB 347.89 ± 40.76 AB 416.88 ± 37.50 ABC 491.45 ± 61.43 AB 478.50 ± 60.82 A
0.0043 mM Mel 254.56 ± 23.46 A 270.60 ± 33.59 BC 328.90 ± 53.78 AB 365.00 ± 73.13 BC 442.22 ± 125.97 AB 470.73 ± 115.67 A
0.000043 mM Mel 257.50 ± 22.37 A 276.25 ± 41.70 ABC 312.88 ± 46.91 B 324.13 ± 91.72 CD 408.63 ± 127.71 B 396.60 ± 86.07 A
0 mM Mel 270.80 ± 35.50 A 302.13 ± 27.12 AB 372.60 ± 57.96 AB 447.22 ± 83.94 AB 550.89 ± 63.18 A 493.13 ± 65.96 A
NaCl Control 274.10 ± 16.20 A 318.70 ± 15.83 A 381.30 ± 33.73 A 454.45 ± 34.45 A 529.56 ± 74.77 AB 506.70 ± 88.59 A
T0 T10 T20 T30 T90 T105
Sham 9.50 ± 4.06 A 9.70 ± 3.92 B 9.40 ± 3.20 C 8.82 ± 2.52 C 7.30 ± 1.25 B 5.86 ± 4.38 B
4.3 mM Mel 10.86 ± 4.71 A 21.60 ± 9.86 A 39.67 ± 8.12 AB 46.63 ± 8.07 AB 61.25 ± 34.02 A 52.14 ± 32.56 A
0.43 mM Mel 11.89 ± 3.95 A 25.38 ± 5.85 A 36.78 ± 13.77 AB 47.00 ± 9.20 AB 48.22 ± 12.40 A 42.50 ± 12.26 AB
0.0043 mM Mel 8.22 ± 2.28 A 19.50 ± 2.88 A 40.70 ± 9.37 AB 46.00 ± 7.36 AB 61.22 ± 28.94 A 62.18 ± 31.21 A
0.000043 mM Mel 8.88 ± 3.09 A 21.25 ± 3.81 A 40.38 ± 5.07 AB 43.00 ± 17.78 AB 57.75 ± 30.29 A 52.40 ± 23.05 A
0 mM Mel 10.70 ± 4.50 A 22.75 ± 8.65 A 46.50 ± 9.25 A 55.11 ± 9.60 A 65.78 ± 30.95 A 59.89 ± 29.17 A
NaCl Control 9.80 ± 2.44 A 24.80 ± 4.05 A 33.40 ± 10.12 B 40.67 ± 6.71 B 44.56 ± 22.09 A 41.00 ± 23.26 AB
Mean ± SD
Mean ± SD
Glu (mg/dL)
Lac (mg/dL)
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Both Glu and Lac remained at basal levels in sham-operated animals while 
they constantly increased in hemorrhaged rats. 
Sham rats were not included when comparing animals that lived to 10 days 
after 60% blood loss and those that died. All sham-operated animals survived to 10 
days since they were not hemorrhaged and including them in these analyses could 
misrepresent the data. A T0, sO2 was higher in non-survivors (p<0.05). tHb was 
lower in 10-day survivors at T10 (p<0.05). Blood Lac was higher at T20 in animals 
that did not live to 10 days (p<0.05). At T90, 10-day survivors had higher pH 
(p<0.01) and pCO2 (p<0.0001); non-survivors had higher sO2 (p<0.05), K
+ 
(p<0.01), and Lac (p<0.001). At T105, pH was higher in rats that lived to 10 days 
(p<0.01); animals that died before the 10 day end point had higher circulating Lac 
(p<0.05). 
Sham-operated animals were also excluded from regression analyses. At 
T0, higher sO2 (p<0.05; HR=1.22) resulted in lower survival. At T10, increased pH 
(p<0.05; HR=301.33) and increased tHb (p<0.05; HR=4.56) decreased survival. 
Reduced tHb at T20 (p<0.05; HR=0.16) reduced survival. Lower pCO2 (p<0.001; 
HR=0.85) and higher K+ (p<0.01) at T90 caused a reduction in survival. At T105, 
lower pH (p<0.001; HR=0.001) and higher Lac (p<0.001; HR=1.03) resulted in 
lower survival. 
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Histopathological Scoring 
Histopathological analyses are important for our research because in 
trauma, death is mostly encountered at three points: 1) within the first hour, 2) 
within the next 24 hours, 3) after days or weeks (Baue, Faist et al. 2000). Since our 
post-operatory monitoring is not comprised of weeks, observing micro anatomical 
changes in different tissues provide information regarding the health status of the 
experimental subjects that survived the entire 10 days. It also helped us identify 
whether those animals would have kept living indefinitely or would have been 
likely to suffer health consequences in the near future. Histological scoring was 
only conducted on the second melatonin dose-ranging study. 
A summary of the results obtained for brain, lung, and small intestine can 
be found in Figure 3.12. 10-day survivors administered 0.000043 mM melatonin 
had lower histopathological scores for intestine compared to those infused with 4.3 
mM melatonin (p<0.05). However, the average score for this treatment represented 
only moderate damage, suggesting that, even though there was a stronger 
inflammatory response in this group, by 10 days after 60% blood loss the 
inflammation is being resolved. 
Plasma Parameters 
Blood samples were collected at six time points: 1) before hypotension (T0), 
2) after 40% blood loss (T10), 3) 10 minutes after 40% blood loss (T20), 4) after 
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60% blood loss (T30), 5) one hour after 60% blood loss (T90), and 6) after blood 
return (T105). Since rats were anticoagulated with 10 IU of heparin via the left 
femoral vein, the centrifugation of the blood samples resulted in the separation of 
cells at the bottom and plasma, not serum, at the top. 
A 
 
B 
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Figure 3.12. Melatonin Dose-Ranging Study II: Histopathological scores for (A) brain, (B) 
lung, and (C) small intestine. 
Rats that survived to the experimental time point of 10 days were euthanized. Infusion of either 4.3 
mM melatonin (n=7), 0.43 mM melatonin (n=7), 0.0043 mM melatonin (n=6), or 0.000043 mM 
melatonin (n=7) was achieved by administering a single 1 ml/kg bolus. The samples for the 0 mM 
melatonin treatment (n=3) were not viable for histological examination. All solutions contained 4 
M BHB and 2% DMSO. A control group was also included and they were administered 4 M NaCl 
with 0.000043 mM melatonin in 2% DMSO (n=3). All sham-operated animals (n=10) were 
included. Bars not present represent damage score values of 0. Data are depicted as mean ± SEM. 
Statistical significance is denoted by the presence of different letters. 
BHB Dose-Ranging Study 
Plasma BHB levels were higher in animals infused with 4 M BHB 
compared to those administered 0.4 M BHB at T20 (p<0.05) and T30 (p<0.01) 
(Figure 13; Table 3.8). These differences were expected because they were 
consistent with the different concentrations infused. At T105, the concentration of 
BHB in the plasma was higher in animals that died between day 0 and day 9 
compared to those that survived until the 10 day end point (p<0.05). Lower BHB 
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levels at T20 (p<0.05) and circulating BHB at T105 (p<0.05) resulted in decreased 
survival. 
 
Figure 3.13. BHB Dose-Ranging Study: Plasma BHB levels. 
Infusion of either 4 M BHB (n=6), 2 M BHB (n=5), or 0.4 M BHB (n=5) was achieved by 
administering a single 1 ml/kg bolus. All solutions contained 4.3 mM melatonin and 10% DMSO. 
Times on the x-axis reflect minutes. Data points are depicted as mean ± SEM. 
Melatonin Dose-Ranging Study II 
TNF-α was selected as a pro-inflammatory cytokine to assess inflammation. 
Since there were sample volume concerns, only one cytokine could be assessed. 
We chose TNF-α for two reasons: 1) It has been reported that maximum changes 
in TNF-α levels occur within the first few hours of hemorrhagic shock (Pati, Gerber 
et al. 2011), which coincides with the plasma samples we had available; and 2) 
TNF-α has been reported to differ from survivors and non survivors both in rat 
(Pati, Gerber et al. 2011) and human (Roumen, Hendriks et al. 1993) studies.  
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Table 3.8. BHB Dose-Ranging Study: Plasma BHB levels. 
 
Statistical significance is denoted by the presence of different letters. Groups not sharing a letter are statistically different (p<0.05). Abbreviations: 
BHB-β-Hydroxybutyrate. 
 
  
4 M BHB 0.38 ± 0.20 A 0.38 ± 0.12 A 3.64 ± 1.93 A 3.57 ± 1.68 A 4.22 ± 4.08 A 1.63 ± 1.11 A
2 M BHB 0.45 ± 0.22 A 0.75 ± 0.75 A 2.88 ± 2.00 AB 2.45 ± 1.77 AB 1.29 ± 0.71 A 1.23 ± 1.21 A
0.4 M BHB 0.33 ± 0.12 A 0.43 ± 0.12 A 1.06 ± 0.77 B 0.86 ± 0.50 B 0.70 ± 0.21 A 0.44 ± 0.04 A
BHB (mM)
T0 T10 T20 T30 T90 T105
Mean ± SD
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Circulating TNF-α levels were determined for a representative sample (n=3 
per treatment) of animals from the sham group as well as animals administered 4.3 
mM melatonin, 0.000043 mM melatonin, 0 mM melatonin, and the NaCl control 
for T20, T30, and T90. No differences were observed between any treatments at 
any time point (Figure 3.14; Table 3.9). However, when shams and NaCl controls 
were not considered, a dose dependent trend was observed at T30 where the higher 
the melatonin administered, the lower the circulating TNF-α. Also at T30, TNF-α 
plasma levels were lower in animals that lived until the end of the experiment 
compared to those that died prematurely (p<0.05). TNF-α did not seem to influence 
survival. 
Table 3.9. Melatonin Dose-Ranging Study II: Plasma TNF-α levels. 
 
Statistical significance is denoted by the presence of different letters. Groups not sharing a letter are 
statistically different (p<0.05). Abbreviations: Mel-Melatonin. TNF-α-Tumor Necrosis Factor 
Alpha. 
 
T20 T30 T90
Sham 34.74 ± 3.12 A 10.73 ± 3.83 A 75.96 ± 48.09 A
4.3 mM Mel 23.55 ± 22.95 A 31.59 ± 45.72 A 20.34 ± 15.43 A
0.000043 mM Mel 19.74 ± 18.36 A 7.64 ± 9.01 A 41.33 ± 17.31 A
0 mM Mel 16.88 ± 10.52 A 38.26 ± 23.69 A 51.68 ± 28.49 A
NaCl Control 11.26 ± 14.33 A 18.05 ± 17.38 A 53.08 ± 22.92 A
TNF-α (pg/mL)
Mean ± SD
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Figure 3.14. Melatonin Dose-Ranging Study II: Plasma TNF-α levels. 
Infusion of either 4.3 mM melatonin (n=3), 0.000043 mM melatonin (n=3), or 0 mM melatonin 
(n=3) was achieved by administering a single 1 ml/kg bolus. All solutions contained 4 M BHB and 
2% DMSO. A control group was also included and they were administered 4 M NaCl with 0.000043 
mM melatonin in 2% DMSO (n=3). Sham-operated animals (n=3) were also included. Times on the 
x-axis reflect minutes. Data points are depicted as mean ± SEM. 
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CHAPTER IV: ISOTONIC EXPERIMENTS 
 96 
 
Survival 
Three-Hour Shock 
The three hour shock protocol was conducted first as a pilot. The idea 
behind it was to see how far we could push the animals to failure and still resuscitate 
them successfully.  p-values for all pairwise comparisons for 24 hours and 10 days 
are summarized in Table 4.1. No sham-operated animals were included in this 
study. The only statistical difference was observed at both 24 hours (Figure 4.1A) 
and 10 days (Figure 4.1B) between LR and 140 mM BHB with 4.3 mM melatonin 
(p<0.05). However, it is worth mentioning that only 3 out of the 20 individuals in 
the whole experiment survived to 10 days; the majority of deaths in all treatment 
groups occurred before 24 hours. Since the overall survival to 10 days of animals 
subjected to 60% blood loss and infused with isotonic fluids at a rate of one time 
the volume lost per hour for three hours is 15%, it becomes evident that the insult 
of 60% blood loss combined with 3 hours without a blood transfusion is too great 
for any isotonic resuscitation fluid to counteract. For these reasons, this study was 
left as a pilot with a sample size of 5 per treatment. 
 
 
 
 97 
 
Table 4.1. Three-Hour Shock Study: Mean survival time in animals subjected to 60% blood 
loss at 24 hours and 10 days. 
Mean survival time calculated as the area under the Kaplan-Meier curve. Units are hours for the 
calculations at 24 hours and days for the calculations at 10 days. n=5 for all treatments. Statistically 
significant p-values are colored in red and underlined. Abbreviations: BHB-β-Hydroxybutyrate. LR-
Lactated Ringer’s. Mel-melatonin. 
 
A 
 
  
24 Hrs 10 Days
16.80 ± 5.58 4.50 ± 2.48
12.13 ± 5.41 0.91 ± 0.55
9.60 ± 3.72 2.20 ± 2.01
5.89 ± 0.11 0.25 ± 0.01
24 Hrs 10 Days
LR/4.3 mM Mel LR 0.4190 0.2360
140 mM BHB/1.5x10-6 mM Mel LR 0.2210 0.2810
140 mM BHB/4.3 mM Mel LR 0.0422 0.0422
140 mM BHB/1.5x10-6 mM Mel LR/4.3 mM Mel 0.9050 0.9070
140 mM BHB/4.3 mM Mel LR/4.3 mM Mel 0.4110 0.4110
140 mM BHB/4.3 mM Mel 140 mM BHB/1.5x10
-6 mM Mel 0.1800 0.1800
Treatment Comparisons
p -value
140 mM BHB/4.3 mM Mel
Treatment
Mean ± SEM
LR
LR/4.3 mM Mel
140 mM BHB/1.5x10-6 mM Mel
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Figure 4.1. Three-Hour Shock: Kaplan-Meier plot of animals subjected to 60% blood loss at 
(A) 24 hours and (B) 10 days. 
Infusion of either LR (n=5), LR plus 4.3 mM Mel (n=5), 140 mM BHB with 1.5x10-6 mM Mel 
(n=5) or 140 mM BHB with 4.3 mM Mel (n=5) was achieved by administering one time the volume 
of blood lost per hour for three hours. Times on the x-axis reflect either hours (A) or days (B) after 
achieving 60% blood loss. 
One-Hour Shock 
A summary of all pairwise comparisons for both 24 hours and 10 days can 
be found in Table 4.2. The only statistical difference observed at 24 hours (Figure 
4.2A) (p<0.05) was between sham-operated animals and those infused with 140 
mM BHB with 1.5x10-6 mM melatonin. At 10 days (Figure 4.2B), the only group 
that was not statistically different from shams was the one administered LR 
(p>0.05).  The 140 mM BHB with 1.5x10-6 mM melatonin treatment also had less 
successful survival times than LR and LR plus 4.3 mM melatonin (p<0.05). The 
addition of 4.3 mM melatonin to LR did not improve survival compared to LR on 
its own. 
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Since the three-hour shock experiments were left as a pilot study, only the 
one-hour shock will be described further. 
A 
 
B 
 
Figure 4.2. One-Hour Shock: Kaplan-Meier plot of animals subjected to 60% blood loss at (A) 
24 hours and (B) 10 days. 
Infusion of either LR (n=10), LR plus 4.3 mM Mel (n=10), 140 mM BHB with 1.5x10-6 mM Mel 
(n=10) or 140 mM BHB with 4.3 mM Mel (n=10) was achieved by administering three times the 
volume of blood lost per hour for one hour. Times on the x-axis reflect either hours (A) or days (B) 
after achieving 60% blood loss. Some lines may be indistinguishable due to overlap. 
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Table 4.2. One-Hour Shock Study: Mean survival time in animals subjected to 60% blood loss 
at 24 hours and 10 days. 
Mean survival time calculated as the area under the Kaplan-Meier curve. Units are hours for the 
calculations at 24 hours and days for the calculations at 10 days. n=10 for all treatments. Statistically 
significant p-values are colored in red and underlined. Abbreviations: BHB-β-Hydroxybutyrate. LR-
Lactated Ringer’s. Mel-melatonin. 
Non-Inferiority Test 
Non-inferiority analyses were conducted to establish if any of the isotonic 
resuscitation fluids employed in these experiments were non-inferior to the 
published hypertonic BHB/M. We declared non-inferiority if the mean survival for 
each treatment was within a two-day Δ of the mean survival for the published 
hypertonic BHB/M. Only the infusion of LR, with or without melatonin, resulted 
in survival times within the specified boundary; both isotonic BHB/M formulations 
were declared inferior to the published BHB/M (Figure 4.3). 
24 Hrs 10 Days
20.34 ± 3.28 7.35 ± 1.59
19.93 ± 3.67 6.73 ± 1.57
11.40 ± 2.82 2.08 ± 1.18
18.60 ± 3.20 5.48 ± 1.62
24.00 10.00
24 Hrs 10 Days
LR Sham 0.1280 0.0555
LR/4.3 mM Mel Sham 0.1280 0.0229
140 mM BHB/1.5x10-6 mM Mel Sham 0.0009 0.00005
140 mM BHB/4.3 mM Mel Sham 0.0555 0.0087
LR/4.3 mM Mel LR 0.9570 0.6910
140 mM BHB/1.5x10-6 mM Mel LR 0.0643 0.0216
140 mM BHB/4.3 mM Mel LR 0.7260 0.4660
140 mM BHB/1.5x10-6 mM Mel LR/4.3 mM Mel 0.0643 0.0351
140 mM BHB/4.3 mM Mel LR/4.3 mM Mel 0.7260 0.6780
140 mM BHB/4.3 mM Mel 140 mM BHB/1.5x10
-6 mM Mel 0.0812 0.0521
Treatment Comparisons
p -value
140 mM BHB/4.3 mM Mel
Treatment
Mean ± SEM
LR
LR/4.3 mM Mel
140 mM BHB/1.5x10-6 mM Mel
Sham
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Figure 4.3 One-Hour Shock Study: Non-inferiority plot of animals subjected to 60% blood 
loss at 10 days. 
Infusion of either LR (n=10), LR plus 4.3 mM Mel (n=10), 140 mM BHB with 1.5x10-6 mM Mel 
(n=10) or 140 mM BHB with 4.3 mM Mel (n=10) was achieved by administering three times the 
volume of blood lost per hour for one hour. Times on the x-axis reflect differences in survival 
times in days after achieving 60% blood loss. Data points are expressed as mean survival in 
days ± 95% Confidence Interval. 
Physiological Constants 
Treatment differences can be observed in Table 4.3 and Figure 4.4. 
MAP was higher in shams compared to all hemorrhaged groups from T10 
to T90 (p<0.05). The only differences (p<0.05) observed between the groups 
subjected to 60% blood loss were at T90 and T105 when the LR plus 4.3 mM 
melatonin group had lower MAP than all other treatment groups. 
Sham-operated animals maintained higher HR than all hemorrhaged 
animals from T10 to T105 (p<0.0001). Rectal temperature was also consistently 
higher in shams compared to hemorrhaged animals from T0 to T105 (p<0.0001). 
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Table 4.3. One-Hour Shock Study: Physiological constant data. 
 
Statistical significance is denoted by the presence of different letters. Groups not sharing a letter are statistically different (p<0.05). Abbreviations: 
BHB-β-Hydroxybutyrate. LR-Lactated Ringer’s. Mel-Melatonin. 
Sham 99.20 ± 12.00 A 84.77 ± 12.57 A 84.77 ± 12.57 A 84.29 ± 11.70 A 97.45 ± 13.33 A 96.18 ± 12.66 A
LR 93.51 ± 10.41 A 26.02 ± 2.16 B 31.71 ± 6.56 B 20.13 ± 2.87 81.48 ± 11.33 B 102.34 ± 17.78 A
LR/4.3 mM Mel 89.31 ± 8.55 A 25.24 ± 1.22 B 30.49 ± 3.26 B 18.68 ± 2.47 56.20 ± 6.93 C 71.56 ± 10.00 B
140 mM BHB/1.5x10-6 mM Mel 87.82 ± 7.77 A 25.27 ± 1.10 B 33.88 ± 7.09 B 21.53 ± 2.72 75.11 ± 13.74 B 92.34 ± 10.35 A
140 mM BHB/4.3 mM Mel 92.41 ± 9.15 A 25.85 ± 1.26 B 31.90 ± 2.12 B 20.97 ± 3.07 72.73 ± 13.25 B 93.11 ± 17.21 A
Sham 360.32 ± 42.95 A 341.18 ± 56.17 A 333.03 ± 51.95 A 316.69 ± 55.00 A 299.54 ± 20.15 A 291.76 ± 23.90 A
LR 346.08 ± 47.54 A 206.47 ± 33.76 B 189.07 ± 20.01 B 266.35 ± 54.69 A 240.36 ± 28.02 B 223.33 ± 25.32 B
LR/4.3 mM Mel 335.15 ± 27.86 A 221.08 ± 50.56 B 201.34 ± 26.22 B 295.52 ± 48.44 A 219.39 ± 17.78 B 210.10 ± 17.37 B
140 mM BHB/1.5x10-6 mM Mel 329.40 ± 41.71 A 223.78 ± 33.76 B 202.17 ± 23.29 B 256.12 ± 50.43 A 239.59 ± 23.17 B 230.54 ± 23.72 B
140 mM BHB/4.3 mM Mel 338.71 ± 54.70 A 253.12 ± 49.37 B 216.29 ± 38.65 B 293.17 ± 66.03 A 237.58 ± 37.04 B 231.79 ± 31.77 B
Sham 35.52 ± 0.37 A 33.83 ±0.48 A 32.86 ± 0.67 A 32.06 ± 0.65 A 29.35 ± 0.56 A 29.03 ± 0.54 A
LR 33.87 ± 0.60 B 31.01 ± 0.78 B 28.62 ± 0.87 B 27.21 ± 1.38 B 24.59 ± 1.41 B 24.33 ± 1.47 B
LR/4.3 mM Mel 33.78 ± .088 B 31.03 ± 0.95 B 28.68 ± 0.83 B 27.07 ± 0.79 B 25.16 ± 0.98 B 24.86 ± 0.92 B
140 mM BHB/1.5x10-6 mM Mel 33.87 ± 0.80 B 30.79 ± 0.92 B 28.46 ± 1.03 B 27.43 ± 1.00 B 25.23 ± 1.22 B 24.91 ± 1.21 B
140 mM BHB/4.3 mM Mel 33.93 ± 0.77 B 31.07 ± 0.82 B 28.60 ± 0.85 B 27.25 ± 0.87 B 25.37 ± 1.04 B 25.32 ± 0.97 B
Rectal Temperature (°C)
Mean ± SD
T0 T10 T20 T30 T90 T105
HR (BPM)
Mean ± SD
T0 T10 T20 T30 T90 T105
MAP (mmHg)
Mean ± SD
T0 T10 T20 T30 T90 T105
 103 
 
A 
 
B      C 
  
Figure 4.4. One-Hour Shock Study: Physiological constant data. 
Infusion of either LR (n=10), LR plus 4.3 mM Mel (n=10), 140 mM BHB with 1.5x10-6 mM Mel 
(n=10) or 140 mM BHB with 4.3 mM Mel (n=10) was achieved by administering three times the 
volume of blood lost per hour for one hour. Times on the x-axis reflect minutes. Data points are 
depicted as mean ± SEM. 
 
Shams were not included in the comparisons between rats that survived to 
10 days after 60% blood loss and those that did not. In sham operations the only 
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bleeding occurs for sampling and all the animals in the group lived to 10 days. 
Including them in these analyses could misstate the results. MAP was higher at T0 
in animals that lived compared to those who died (p<0.05); the opposite was true 
at T20 (p<0.05). No other physiological parameters showed statistical differences 
between 10-day survivors and non-survivors. 
Sham rats were also excluded from our Cox Proportional Hazards 
regression analyses. Higher MAP at T20 resulted in lower survival (p<0.05; 
HR=1.11). Lower HR was associated with lower survival at T0 (p<0.05; HR=0.98) 
and T30 (p<0.05; HR=0.99); the opposite was observed at T20 (p<0.01; HR=1.04). 
Rectal temperature had no effect on survival at any time point. 
Whole Blood Parameters 
All treatment differences are summarized in Table 4.4 and Figure 4.5. 
A 
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Figure 4.5. One-Hour Shock Study: Whole-blood parameter data. 
Infusion of either LR (n=10), LR plus 4.3 mM Mel (n=10), 140 mM BHB with 1.5x10-6 mM Mel 
(n=10) or 140 mM BHB with 4.3 mM Mel (n=10) was achieved by administering three times the 
volume of blood lost per hour for one hour. Times on the x-axis reflect minutes. Data points are 
depicted as mean ± SEM. 
Statistical differences in tHb were observed from T10 to T90 between sham-
operated animals and all hemorrhaged groups (p<0.01). This is to be expected as 
the loss of blood is accompanied by a reduction in red cell mass(Carey, Lowery et 
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al. 1971). Furthermore, the infusion of large volumes of resuscitation fluids is 
accompanied by substantial hemodilution. A blood transfusion at T105 returned 
tHb to levels close to those of the starting point in hypovolemic animals. 
Statistical differences in pH were only observed at T10 between shams and 
hemorrhaged animals (p<0.05). However, the mean values for all groups at all time 
points stayed relatively close to the physiologically neutral value of 7.4. 
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Table 4.4. One-Hour Shock Study: Whole-blood data. 
 
Sham 13.02 ± 0.78 A 12.17 ± 0.95 A 12.24 ± 0.77 A 11.83 ± 0.86 A 11.69 ± 1.54 A 8.35 ± 5.28 A
LR 12.06 ± 0.98 A 10.19 ± 0.52 B 8.63 ± 1.14 B 8.59 ± 0.44 B 5.81 ± 0.62 B 8.24 ± 0.60 A
LR/4.3 mM Mel 12.62 ± 0.45 A 10.37 ± 0.44 B 8.64 ± 0.80 B 8.80 ± 0.89 B 5.19 ± 0.49 B 7.79 ± 0.65 A
140 mM BHB/1.5x10-6 mM Mel 12.33 ± 0.78 A 10.42 ± 0.80 B 8.94 ± 0.68 B 8.89 ± 0.97 BC 6.68 ± 1.63 B 8.09 ± 1.42 A
140 mM BHB/4.3 mM Mel 12.79 ± 0.76 A 10.66 ± 0.80 B 7.94 ± 0.73 B 6.48 ± 3.32 C 5.64 ± 0.90 B 7.60 ± 1.12 A
Sham 7.40 ± 0.04 A 7.38 ± 0.08 B 7.38 ± 0.06 A 7.33 ± 0.16 A 7.27 ± 0.19 A 7.27 ± 0.14 A
LR 7.45 ± 0.04 A 7.53 ± 0.05 A 7.37 ± 0.15 A 7.38 ± 0.16 A 7.33 ± 0.08 A 7.36 ± 0.14 A
LR/4.3 mM Mel 7.43 ± 0.05 A 7.50 ± 0.06 A 7.42 ± 0.05 A 7.47 ± 0.12 A 7.33 ± 0.09 A 7.35 ± 0.11 A
140 mM BHB/1.5x10-6 mM Mel 7.41 ± 0.06 A 7.44 ± 1.11 AB 7.29 ± 0.20 A 7.34 ± 0.25 A 7.38 ± 0.16 A 7.38 ± 0.14 A
140 mM BHB/4.3 mM Mel 7.43 ± 0.06 A 7.50 ± 0.08 A 7.41 ± 0.08 A 7.46 ± 0.09 A 7.42 ± 0.05 A 7.44 ± 0.06 A
Sham 96.15 ± 2.80 A 95.99 ± 1.46 A 92.14 ± 4.21 B 94.90 ± 4.04 A 95.66 ± 2.59 A 96.51 ± 0.70 A
LR 89.24 ± 5.66 B 96.42 ± 0.99 A 96.11 ± 1.39 A 95.70 ± 1.21 A 93.43 ± 4.45 A 93.21 ± 4.46 A
LR/4.3 mM Mel 86.57 ± 4.23 B 95.31 ± 2.19 A 95.74 ± 0.82 A 95.68 ± 0.93 A 97.00 ± 2.28 A 94.34 ± 2.16 A
140 mM BHB/1.5x10-6 mM Mel 86.93 ± 2.61 B 95.86 ± 1.37 A 95.66 ± 0.71 A 94.91 ± 2.50 A 95.90 ± 1.00 A 96.01 ± 1.43 A
140 mM BHB/4.3 mM Mel 88.64 ± 3.45 B 96.00 ± 1.41 A 95.97 ± 1.32 A 96.03 ± 1.00 A 95.64 ± 0.77 A 95.45 ± 2.47 A
Sham 4.02 ± 0.26 A 3.57 ± 0.33 B 3.56 ± 0.25 B 3.75 ± 0.42 B 4.26 ± 0.50 A 4.44 ± 0.52 A
LR 3.83 ± 0.29 A 4.14 ± 0.43 A 4.38 ± 0.53 A 5.01 ± 0.79 A 3.35 ± 0.32 AB 3.47 ± 0.26 BC
LR/4.3 mM Mel 4.00 ± 0.34 A 4.49 ± 0.28 A 4.17 ± 0.62 AB 5.32 ± 0.53 A 3.93 ± 0.78 AB 3.98 ± 0.73 AB
140 mM BHB/1.5x10-6 mM Mel 4.08 ± 0.33 A 4.49 ± 0.34 A 4.47 ± 0.78 A 5.41 ± 0.48 A 2.90 ± 1.41 B 2.79 ± 0.98 CD
140 mM BHB/4.3 mM Mel 3.90 ± 0.39 A 4.28 ± 0.44 A 3.90 ± 0.44 AB 4.75 ± 0.44 A 2.75 ± 0.80 B 2.30 ± 0.31 D
K
+
 (mmol/L)
Mean ± SD
T0 T10 T20 T30 T90 T105
sO2 (%)
Mean ± SD
T0 T10 T20 T30 T90 T105
pH
Mean ± SD
T0 T10 T20 T30 T90 T105
tHb (g/dL)
Mean ± SD
T0 T10 T20 T30 T90 T105
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Sham 139.40 ± 1.65 A 142.36 ± 2.25 A 142.50 ± 1.96 A 142.36 ± 3.23 A 140.55 ± 2.95 A 137.63 ± 4.31 A
LR 136.13 ± 3.31 A 133.89 ± 6.86 B 137.13 ± 9.28 A 133.00 ± 10.96 B 135.70 ± 14.28 A 139.89 ± 3.14 A
LR/4.3 mM Mel 137.10 ± 4.28 A 136.70 ± 4.47 B 141.10 ± 5.55 A 136.10 ± 4.58 AB 141.00 ± 3.56 A 140.22 ± 3.70 A
140 mM BHB/1.5x10-6 mM Mel 137.78 ± 4.38 A 136.44 ± 4.33 B 141.11 ± 4.01 A 134.56 ± 5.10 AB 137.75 ± 6.52 A 137.44 ± 7.04 A
140 mM BHB/4.3 mM Mel 135.50 ± 4.84 A 135.25 ± 3.66 B 141.00 ± 5.45 A 135.50 ± 4.38 AB 134.83 ± 2.48 A 134.86 ± 8.09 A
Sham 1.40 ± 0.03 A 1.33 ± 0.06 B 1.36 ± 0.03 A 1.36 ± 0.07 A 1.43 ± 0.07 A 1.39 ± 0.06 A
LR 1.34 ± 0.07 A 1.37 ± 0.13 AB 1.33 ± 0.15 A 1.41 ± 0.21 A 1.26 ± 0.20 AB 1.33 ± 0.05 A
LR/4.3 mM Mel 1.39 ± 0.09 A 1.45 ± 0.09 A 1.33 ± 0.17 A 1.45 ± 0.15 A 1.27 ±0.12 AB 1.24 ± 0.10 AB
140 mM BHB/1.5x10-6 mM Mel 1.39 ± 0.09 A 1.46 ± 0.07 A 1.38 ± 0.15 A 1.48 ± 0.10 A 1.11 ± 0.24 BC 1.11 ± 0.23 BC
140 mM BHB/4.3 mM Mel 1.35 ± 0.11 A 1.42 ± 0.11 AB 1.32 ± 0.14 A 1.41 ± 0.14 A 1.00 ± 0.13 C 0.98 ± 0.04 C
Sham 109.00 ± 7.83 A 110.91 ± 6.04 A 109.50 ± 2.76 A 112.18 ± 7.29 A 114.36 ± 5.78 AB 118.89 ± 10.62 A
LR 109.88 ± 5.41 A 110.67 ± 7.89 A 115.50 ± 6.46 A 116.56 ± 10.90 A 124.40 ± 18.75 A 115.33 ± 4.56 AB
LR/4.3 mM Mel 107.50 ± 6.52 A 107.30 ± 7.06 A 115.60 ± 9.90 A 111.60 ± 10.63 A 112.30 ± 5.54 AB 112.89 ± 5.16 AB
140 mM BHB/1.5x10-6 mM Mel 108.22 ± 8.51 A 105.89 ± 2.42 A 112.67 ± 5.85 A 108.67 ± 3.84 A 90.13 ± 12.70 C 97.44 ± 16.33 B
140 mM BHB/4.3 mM Mel 111.25 ± 7.54 A 112.88 ± 15.55 A 118.00 ± 11.93 A 116.25 ± 15.06 A 97.83 ± 18.79 BC 113.57 ± 25.07 AB
Sham 263.10 ± 23.85 A 234.36 ± 32.41 B 240.20 ± 35.12 B 249.18 ± 56.80 B 264.46 ± 59.72 B 224.00 ± 123.63 B
LR 268.74 ± 60.65 A 309.89 ± 41.62 AB 335.13 ± 52.27 AB 386.75 ± 75.19 A 325.75 ± 53.73 AB 336.25 ± 70.76 AB
LR/4.3 mM Mel 270.50 ± 45.73 A 331.63 ± 80.84 AB 336.88 ± 69.48 A 404.75 ± 42.71 A 348.00 ± 86.26 AB 359.71 ± 53.66 AB
140 mM BHB/1.5x10-6 mM Mel 280.88 ± 50.41 A 366.50 ± 11.34 A 393.63 ± 90.60 A 468.00 ± 114.73 A 384.75 ± 105.59 A 362.11 ± 102.88 A
140 mM BHB/4.3 mM Mel 266.25 ± 5.61 A 318.88 ± 114.38 AB 342.00 ± 94.68 A 450.67 ± 137.26 A 343.00 ± 67.48 AB 338.00 ± 103.27 AB
Glu (mg/dL)
Mean ± SD
T0 T10 T20 T30 T90 T105
Cl
-
 (mmol/L)
Mean ± SD
T0 T10 T20 T30 T90 T105
Ca++ (mmol/L)
Mean ± SD
T0 T10 T20 T30 T90 T105
Na+ (mmol/L)
Mean ± SD
T0 T10 T20 T30 T90 T105
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Statistical significance is denoted by the presence of different letters. Groups not sharing a letter are statistically different (p<0.05). Abbreviations: 
BHB-β-Hydroxybutyrate. LR-Lactated Ringer’s. Mel-Melatonin. 
 
 
 
Sham 9.50 ± 4.06 A 9.70 ± 3.92 B 9.40 ± 3.20 B 8.82 ± 2.52 B 7.30 ± 1.26 B 5.86 ± 4.38 C
LR 13.00 ± 3.07 A 27.67 ± 6.96 A 47.88 ± 7.53 A 55.56 ± 8.63 A 55.40 ± 18.70 A 45.33 ± 8.87 A
LR/4.3 mM Mel 11.50 ± 1.90 A 28.60 ± 3.13 A 42.60 ± 7.32 A 59.60 ± 15.72 A 58.00 ± 18.73 A 47.56 ± 13.17 A
140 mM BHB/1.5x10-6 mM Mel 10.78 ± 2.49 A 29.89 ± 5.40 A 50.00 ± 7.31 A 62.78 ± 12.41 A 39.43 ± 11.19 A 34.88 ± 9.25 AB
140 mM BHB/4.3 mM Mel 12.38 ± 5.04 A 21.63 ± 11.31 A 44.00 ± 11.16 A 58.57 ± 16.23 A 43.83 ± 16.02 A 29.86 ± 12.09 B
Lac (mg/dL)
Mean ± SD
T0 T10 T20 T30 T90 T105
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At T0, sO2 was somewhat decreased in all groups except shams. This could 
be a result of the anesthetic induction with isoflurane. The only other difference 
observed was at T20, when shams seemed to have slightly less oxygenated blood 
than shams. However, those differences were not of clinical concern. 
Increased blood K+ levels are common in hemorrhagic shock (Carey, 
Lowery et al. 1971). K+ levels increased as blood loss occurred. Shams’ circulating 
K+ was lower from T0 to T30 but progressively increased. After the one-hour shock 
period, animals infused with either of the LR treatments maintained blood K+ at 
levels close to baseline. From T90 to T105, both of the BHB/M groups had mean 
K+ concentrations below the normal range of 3.9-9.2 mmol/L (Sharp and Villano 
1998). 
Hyponatremia occurs with hemorrhage (Carey, Lowery et al. 1971). Some 
differences were observed between shams and hemorrhaged animals at T10 and 
T30 (p<0.05). During the hemorrhagic phase, Na+ levels in the hypovolemic groups 
seemed to parallel blood pressure. Through the one-hour shock period, circulating 
Na+ returned to homeostatic levels. This is probably due to the Na+ content in the 
solutions infused. 
Though hemorrhage did affect circulating Ca++ levels, those changes were 
within the reference values (1.2-1.6 mmol/L) (Sharp and Villano 1998). However, 
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blood Ca++ fell below the normal range in animals administered either one of the 
isotonic BHB/M formulations used in this study. These differences were 
statistically significant at T90 (p<0.05) and T105 (p<0.01). 
Cl- levels fluctuated slightly during blood withdrawal, reaching levels above 
the normal range of 84-110 mmol/L (Sharp and Villano 1998) at T20. At T90, the 
administration of isotonic BHB/M formulations resulted in Cl- concentrations on 
the low end of the reference values while animals infused with LR had circulating 
Cl- levels above the normal range. A blood transfusion brought blood Cl- to levels 
close to baseline in all hypovolemic groups. 
Sham-operated animals had lower Glu and Lac levels than all other 
treatments (p<0.05) at all time points except T0, consistent with a normal response 
to shock (Carey, Lowery et al. 1971). 
Blood Glu levels increased after T10 in hemorrhaged animals, as expected 
in a normal response to shock (Carey, Lowery et al. 1971).  
Sham rats had lower blood Lac than all hemorrhaged groups from T10 to 
T105 (p<0.01). It should also be pointed out that the administration of LR, with or 
without melatonin, resulted in slightly higher circulating Lac than when the rats 
were infused with either one of the isotonic BHB/M solutions. 
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Sham rats were excluded from the comparisons between animals that lived 
to 10 days after 60% blood loss and those that died. All sham-operated animals 
survived to the 10 days endpoint. Hence their inclusion in these analyses could bias 
the data. tHb at T20 and Ca++ at T90 were lower in animals that died compared to 
those that lived to 10 days (p<0.05).  
Sham-operated animals were also excluded from regression analyses. Low 
pH at T10 negatively influenced survival (p<0.05; HR=0); the opposite was 
observed at T30 (p<0.05; HR=0.03). Higher sO2 at T90 resulted in lower survival 
(p<0.05; HR=1.78). Lower Glu at T0 (p<0.05; HR=0.96) and T105 (p<0.05; 
HR=0.98) ensued lower survival; a reversed trend was observed at T10 (p<0.05; 
HR=1.02) and T90 (p<0.05; HR=1.02). 
Histopathological Scoring 
Histopathological damage scores can be graphically observed in Figure 4.6. 
Statistical differences where only observed in lung. Shams had less evidence of 
tissue damage than 10-day survivors administered LR, LR plus melatonin, or 140 
mM BHB with 4.3 mM melatonin (p<0.01). It is possible that the lungs underwent 
some level of edema and congestion as a response to the fluid overload common to 
isotonic resuscitation. However, since the damage scores were only moderate, we 
can infer that the injury to the tissue is on its way to a successful resolution. 
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Figure 4.6. One-Hour Shock Study: Histopathological scores for (A) brain, (B) lung, and (C) 
small intestine. 
Rats that survived to the experimental time point of 10 days were euthanized. Infusion of either LR 
(n=7), LR plus 4.3 mM Mel (n=6), 140 mM BHB with 1.5x10-6 mM Mel (n=1) or 140 mM BHB 
with 4.3 mM Mel (n=5) was achieved by administering three times the volume of blood lost per 
hour for one hour.  All sham-operated animals (n=10) were included. Bars not present represent 
damage score values of 0. Data are depicted as mean ± SEM. Statistical significance is denoted by 
the presence of different letters. 
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CHAPTER V: DISCUSSION 
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In short, our experiments support an adjustment in the composition of the 
previously published hypertonic BHB/M which is intended to be infused as a low 
volume (1 ml/kg) resuscitation fluid. The ketone component of BHB/M, the D-
stereoisomer of β-Hydroxybutyrate, should remain to be administered at a 
concentration that results in 4 mM circulating BHB. Melatonin can be lowered to a 
concentration a million-fold lower than the original concentration of 43 mM 
without affecting survival rate. Bringing melatonin to a lower level means the use 
of DMSO can be greatly reduced. This is advantageous since there is still much 
controversy over the use of DMSO (Davis 1984). We also demonstrated that a slow 
infusion after a bolus administration is not necessary. This is a highly desirable trait 
as it increases the feasibility for self-administration in warfare scenarios. Finally, 
administering BHB/M as an isotonic resuscitation fluid does not provide the same 
survival benefit as the standard of care. 
In the first set of experiments, we observed that a single 1 ml/kg bolus of 
BHB/M provides similar survival benefits as a bolus plus a slow infusion. 
Previously, BHB/M had been administered as a 1 ml/kg bolus followed by a 100 
µl/hr slow infusion (Klein, Wendroth et al. 2010). We decided to explore the 
feasibility of infusion BHB/M as a single bolus only. A single bolus is more 
practical in terms of self-administration. Our results show that administering 
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BHB/M as a single 1 ml/kg bolus had no statistically different survival compared 
to the administration of a 1 ml/kg bolus followed by a 100 µl/hr infusion for one 
hour. In fact, animals that were administered a single bolus lived longer than those 
in which a slow infusion was continued. The lack of statistical difference could be 
a result of a small sample size.  However, there are a few mechanistic interpretations 
that could explain these results. 
Osmolar overload and the potential of causing hyperosmolar comma is a 
concern when utilizing hypertonic fluids as a resuscitative strategy. Normal plasma 
osmolality ranges from 280 to 295 mOsm/l (Kreimeier and Messmer 2002). Plasma 
osmolalites higher than 320 mOsm/l can be tolerated if transient (Kramer 2003). 
However, if allowed to persist they can develop negative neurological 
consequences (Kreimeier and Messmer 2002; Kramer 2003). Other risks associated 
with the administration of hypertonic resustitation fluids include hypernatremia, 
hypokalemia, hemolysis, and increased clotting times, among others (Kreimeier 
and Messmer 2002). 
The organism has an innate capacity to compensate for acute changes in 
plasma osmolarity and electrolyte imbalance. Per contra, chronic alterations may 
overwhelm the body’s capacity to countervail physiological alterations. A single 
bolus potentially allows the organism to balance the osmolarity and electrolyte 
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content of the blood.  Continuing to infuse a hypertonic solution may exceed the 
individual’s ability to compensate for the osmolar load and electrolyte imbalance. 
We also demonstrated that it is important to maintain circulating BHB 
at a 4 mM concentration in order to obtain maximum survival. Our data 
supports maintaining BHB at a 4 M concentration when administered at a volume 
of 1 ml/kg. Our collaborators conducting the pig model experiments have observed 
similar survival benefits when administering 2 M BHB at 2 ml/kg (data not shown). 
Empirically, it can be inferred that both modes of administration would result in an 
overall bodily concentration of 4 mM BHB. This assumption is supported by our 
data on plasma BHB (Figure 3.13). 
The BHB concentration is responsible a fluid shift from the intracellular 
space into the intravascular space. A 4 M BHB solution contains 8,000 mOsm/l; 
4,000 mOsm/l from the BHB itself and 4,000 mOsm/l from the sodium content as 
we use the sodium salt form of BHB. The administration of a hypertonic solution 
results in an osmotic gradient that rapidly mobilizes intracellular water into the 
intravascular space (Guyton and Hall 2001; Kreimeier and Messmer 2002), 
restoring MAP and hence CO and perfusion (Kreimeier and Messmer 2002; Kramer 
2003). Reducing the concentration of circulating BHB would result in a decrease 
of the plasma expansion attributed to the hypertonic effect. However, volume 
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kinetics experiments would be required to confirm this theory by quantifying the 
changes in the distribution of bodily fluids. 
BHB is also important in the maintenance of ATP production. BHB can be 
enzymatically converted into two molecules of acetyl-CoA which can directly enter 
the Krebs cycle and maintain energy production (Kashiwaya, Takeshima et al. 
2000). Administering BHB at lower concentrations would issue a direct decline in 
ATP availability; reducing the concentration by 10-fold would be insufficient to 
increase plasma BHB above the baseline circulating levels (~0.4 mM) observed in 
our study (Figure 3.13) and by Klein et al (2010). 
A 4 M NaCl solution also contains 8,000 mOsm/l; 4,000 from the sodium 
and 4,000 from the chloride. However, a 1ml/kg bolus of 4 M NaCl could not 
support survival as effectively as a 1ml/kg bolus of 4 M BHB. Since NaCl does 
not provide any nutritional support, it only has the circulatory benefits common to 
hypertonic resuscitation fluids. It does not have an effect on ATP production, like 
BHB does, which is essential for the maintenance of normal or near normal cellular 
function. 
It would be interesting to investigate concentrations higher than 4 M BHB 
in the composition of BHB/M, however, 4 M is already in the upper limits of the 
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water solubility of the compound and in order to conduct those experiments a new 
approach for diluting the components would be required. 
In our rat model of hemorrhagic shock, melatonin provides therapeutic 
effects at very low concentrations. The infusion of a 1 ml/kg bolus of 4 M BHB 
with melatonin concentrations a million-fold lower than the previously published 
formulation (Klein, Wendroth et al. 2010) still supported survival (Figure 3.5). 
Melatonin peaks in rats are ~8.61 × 10-7 mM (Benot, Molinero et al. 1998). Hence, 
administering a 1 ml/kg bolus of 43 mM melatonin, the way it occurred in the 
experiments by Klein et al (2010), would result in plasma levels almost fifty 
thousand times higher than peak, oversaturating the system.  
Though the concentration of melatonin can be greatly reduced, it cannot be 
eliminated for we have evidence that melatonin is important for survival. 4 M 
BHB without the addition of melatonin resulted in the same survival 10-day 
survival (30%) as 4 M NaCl with melatonin (Figure 3.5). As stated above, 4 M 
NaCl does not provide nutritional support. However, our NaCl control group had 
0.000043 mM melatonin included in its composition. There is evidence that 
supports the assumption that having melatonin in its formulation would provide 
ROS scavenging and anti-inflammatory effects (Cuzzocrea and Reiter 2001; Mayo, 
Sainz et al. 2005) and hence a survival benefit. When BHB was administered 
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without melatonin, initial survival was observed, but it could not be supported long 
term. This provides evidence that melatonin may be responsible for the long term 
survival effects of BHB/M. 
A minor aspect of our experiments aimed at determining if the active 
pharmacological induction of hypothermia enhanced survival. Passive cooling was 
an important component of the studies by Klein et al (2010). It is possible that the 
mechanism by which hypothermia provides a therapeutic effect relies on the fact 
that a single °C reduction in body temperature can result in a 6 to 10% drop in 
metabolic rate (Polderman 2009). Decreasing metabolic rate lowers the individual’s 
energy and oxygen requirements. 
In hibernation, a reduction in body temperature occurs as the result of 
decreased metabolic rate (Heldmaier, Klingenspor et al. 1999; Ortmann and 
Heldmaier 2000), not the other way around.  It has been suggested that the decline 
in metabolic rate in hibernators may be related to changes in circulating thyroid 
hormone since thyroid hormone is a major determinant of an organism’s overall 
metabolic rate. 3-iodothyronamine (T1AM) is a recently discovered derivative of 
thyroxine (T4), the predominant form of thyroid hormone, is found in the brain and 
blood of Siberian hamsters, a hibernating species (Piehl, Heberer et al. 2008). 
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Scanlan et al (2004) showed that intraperitoneal injections of T1AM rapidly 
lower body temperature and slow heart rate in mice. T1AM at 50 mg/kg lowered 
body temperature from 37° to 31°C within 30 minutes.  These mice’s phenotype 
mimicked natural hibernation for they were inactive, in a curled position, and cool 
to the touch; this phenotype remained for 6 to 8 hours after injection. 
In our rat experiments, a slight reduction in temperature was observed in 
normotensive animals administered T1AM intravenously at either 50 mg/kg, 25 
mg/kg, 10 mg/kg, 2 mg/kg, or 0 mg/kg. However, administration of T1AM in 
normotensive rats did not influence temperature more than anesthesia (Figure 
3.9). We believe that the use of an anesthetic could be concealing the hypothermic 
effects of T1AM, if any. In order to confirm these suspicions, consideration was 
given to conducting these experiments without anesthesia. However, despite T1AM 
been known to induce a torpor-like state which is also consistent with a response to 
anesthesia, Scanlan et al (2004) do not report data on analgesia. Hence, though an 
animal may seem unconscious, they may still be able to experience pain. 
Considering the level of agony and distress the surgical procedure causes to the 
animals, we do not find it reasonable to execute the surgeries without an anesthetic 
agent. 
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We decided not to explore the possibility of adding T1AM to BHB/M 
because of the results described above and due to statistical concerns.  In our 
previous experiments we have found no statistical differences in survival (p>0.05) 
between sham-operated animals and hypovolemic rats administered both 4 M BHB 
and melatonin at any concentration (Figure 3.5). Animals that were administered 
BHB without melatonin or melatonin with NaCl observed survival statistically 
lower (p<0.05) than shams. Not observing statistically significant variation in 
survival between our different treatment groups for the melatonin dose-ranging 
study and the shams complicates determining if the adjunction of T1AM to BHB/M 
could improve outcomes of hemorrhagic shock since, with the current statistical 
tools and tests available, establishing differences between the effects of BHB/M 
with and without T1AM is not likely considering there are already no differences 
between shams and the different formulations of BHB/M tested. 
We decided to evaluate the efficacy of BHB/M as an isotonic formulation. 
We found that the isotonic form of BHB/M is not efficient for sustaining 
survival when compared to the standard of car (LR). It was necessary for us to 
conduct isotonic experiments because the standard of care for hemorrhagic shock 
is the administration of isotonic non-sanguineous resuscitation fluids (Falk, O'Brien 
et al. 1992); the use of hypertonic solutions is still contentious and not widespread 
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(Kreimeier and Messmer 2002). Isotonic solutions need to be administered in large 
volumes because their electrolyte content allows for water to move freely between 
the intravascular compartments (Moon, Hollyfield-Gilbert et al. 1994). 
Furthermore, infusing abundant quantities of fluid may result in fluid accumulation 
and edema, particularly in the lung (Imm and Carlson 1993). There is no “ideal” 
resuscitation fluid currently available, and though LR is very effective, many 
researchers are still focusing on the development of the resuscitative strategy that 
is effective at small infusion volume, can be administered rapidly, has sustained 
effects, and is safe (Kyes and Johnson 2011). 
In our rat model of hemorrhagic shock, LR administration was more 
efficient at sustaining survival after 60% blood loss both at 24 hours and 10 days 
after surgery than any other isotonic treatment used in these experiments (Figure 
4.2). This may be because parenteral fluids should have a similar composition to 
normal plasma (Hartmann 1934). LR provides essential mineral constituents of 
blood which isotonic BHB/M does not. 
Although we did not find any electrolyte effects on survival, LR, with or 
without melatonin, provided better electrolyte support than 140 mM BHB with 
1.5x10-6 mM Mel or 140 mM BHB with 4.3 mM Mel as evident by the fact that the 
treatments containing LR maintained higher values for K+, Na+, Ca++, and Cl-, 
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regardless of statistical significance. (Figure 4.5) We speculate that the 
administration of a mixture of electrolytes that is similar to that of the plasma is 
important for sustained survival when the resuscitation strategies involve isotonic 
fluids. 
In an effort to identify whether physiological constants (MAP, HR, and 
rectal temperature) whole-blood (tHb, pH, sO2,  pO2, pCO2, K
+, Na+, Ca++, Cl-, Glu, 
and Lac), and plasma (BHB and TNF-α) parameters measured during the 
hemorrhagic shock protocol that could serve as a predictor of survival we 
conducted analyses comparing 10-day survivors to non-survivors. We also ran Cox 
Proportional Hazards regression models expecting to identify relationships between 
survival and all other data. We found that physiological constant, whole-blood, 
and plasma parameter data do not provide information that can consistently 
help predict survival. Though some statistically significant observations were 
made, they were not consistent through the shock procedure. Furthermore, they 
were often contradictory from one time point to the next. It is possible that none of 
the parameters measured particularly affect survival individually. 
Melatonin has been suggested to have anti-inflammatory effects (Cuzzocrea 
and Reiter 2001; El-Shenawy, Abdel-Salam et al. 2002; Mathes, Kubulus et al. 
2008; Wu, Tsou et al. 2008). It has been shown to reduce tissue damage (Reiter, 
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Calvo et al. 2000; Cuzzocrea and Reiter 2001; Yang, Subeq et al. 2011) and prevent 
multiple organ failure (Crespo, Macías et al. 1999; Wu, Tsou et al. 2008). One of 
the proposed mechanisms for this protection is based on evidence suggesting 
melatonin can prevent the expression of adhesion molecules (Cuzzocrea and Reiter 
2001; Kang, Ahn et al. 2001). 
In the hypertonic resuscitation experiments, our histological results showed 
that the lowest dose of melatonin administered, 0.000043 mM, had statistically 
higher injury scores in small intestine than the one administered the highest dose of 
4.3 mM in our second melatonin dose-ranging study. Furthermore, the melatonin 
response observed at T30 in TNF-α levels also support the idea of a dose-dependent 
anti-inflammatory action of melatonin. Hence melatonin may have dose-
dependent anti-inflammatory properties. It is possible that other dose-dependent 
differences were masked by statistical variability, unequal variances, and low 
sample size. However, these differences do not seem to affect survival, supporting 
a reduction in the concentration of melatonin in the composition of BHB/M in a rat 
model. 
Surviving to 10 days following 60% blood loss is no guarantee of indefinite 
survival. Many successfully resuscitated patients may have delayed deaths (Deitch 
1992; Fink, Hayes et al. 2008) as the inflammatory and immunologic alterations 
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triggered by trauma and hemorrhage may lead lead to a series of complications 
known as multiple organ failure (MOF) (Yao, Redl et al. 1998). In MOF, organ 
injury is not directly caused by exogenous factors (Deitch 1992), instead, it is the 
result of disproportionate self-destructive inflammation (Roumen, Hendriks et al. 
1993; Yao, Redl et al. 1998; Rotstein 2000). In this condition, the host’s own 
immune system engages in an actively destructive process. The immunological 
conditions leading to tissue damage include, amongst others, release of pro-
inflammatory cytokines and changes in endothelial permeability (Ayala, Wang et 
al. 1991; Deitch 1992; Deitch, Xu et al. 1994; Martin, Boisson et al. 1997; Yao, 
Redl et al. 1998; Meng, Dyer et al. 2000; Keel and Trentz 2005; Yang, Subeq et al. 
2011).  
MOF is unique in the sense that it can lead to the malfunction of organs not 
involved in the original traumatic insult and that days to weeks can pass before the 
compromise of organs not involved in the original insult (Deitch 1992; Roumen, 
Hendriks et al. 1993). It is the leading cause of death in surgical intensive care units, 
accounting for 50-80% of the unit’s defunctions (Deitch 1992; Roumen, Hendriks 
et al. 1993; Rotstein 2000).  
We conducted histopathological analyses to estimate whether our animals 
were likely to exhibit deaths due to MOF past the 10 days they were monitored. 
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Since our post-operatory monitoring is not comprised of weeks, observing micro 
anatomical changes in different tissues provides information regarding the health 
status of the experimental subjects that survived the entire 10 days and helps us 
identify whether those animals would have kept living indefinitely or were likely 
to suffer from MOF and die in the near future. The central nervous system remains 
the major single limiting organ after injury. Furthermore, the “gut hypothesis” 
states that ischemia causes changes in the permeability of the intestine that alters 
the immunological function of the gut and increases systemic translocation of 
bacteria, leading to the development of a systemic inflammatory response 
syndrome (SIRS), followed by an acute respiratory distress syndrome (ARDS), and 
finally MOF (Baue, Faist et al. 2000). For these reasons, we decided to examine the 
brain, intestine, and lungs. 
 In both the hypertonic and the isotonic experiments, the highest average 
damage scores were only moderate, suggesting that the injury to the tissues was on 
its way to a successful resolution. Based on these results it appears that BHB/M 
reduces the risk of Multiple Organ Failure. 
 To recapitulate, BHB/M is successful at achieving 10-day survival in rats 
hemorrhaged to 60% of their calculated blood volume through immediate, short-
term, and long term mechanisms. The immediate effects can be attributed to its 
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hyperosmolarity; increases in the solute concentration of the blood shifts 
intracellular water intro the intravascular space, increasing MAP, CO, and systemic 
perfusion. In the short term, BHB provides nutritional support allowing for the 
maintenance of energy production and cellular function; melatonin scavenges for 
potentially damaging ROS. It can be inferred that the long-term effects of BHB/M 
are associated with the immunomodulatory effects of melatonin. 
Future Directions 
Subsequent experiments should be aimed at identifying the mechanisms, 
beyond speculation, by which rats hemorrhaged to 60% of their calculated blood 
volume achieve 10 day survival after a 1 mg/kg infusion of BHB/M. Thus far, we 
do not have any evidence to substantiate our proposed mechanisms of action of 
BHB/M. 
Volume kinetics experiments would provide information regarding changes 
in the distribution of bodily fluids after infusion. This would either confirm or refute 
the idea that BHB/M mobilizes intracellular water into the intravascular space. 
Additionally, they would offer a quantitative analysis of volume and rate of plasma 
expansion plus data on distribution and elimination of fluids. 
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Special attention should be paid to the protective mechanisms of melatonin, 
particularly to those involving the immune function. It is well accepted that 
melatonin has immunomodulatory roles (Mayo, Sainz et al. 2005). However, we 
do not know where in the inflammatory cascade melatonin exerts its effects in the 
hemorrhagic shock scenario. Does it reduce pro-inflammatory cytokine production 
and/or increase anti-inflammatory cytokine production? Does it affect the 
expression of adhesion molecules? Does it interfere with leukocyte-endothelium 
interactions? 
Our assessment of plasma TNF-α levels could be expanded to include other 
pro-inflammatory cytokines, such as IL-1 and IL-6, as well as anti-inflammatory 
cytokines, like IL-4 and IL-10. Furthermore, their values should not be assessed 
individually as a strong pro-inflammatory response may be counteracted by a strong 
anti-inflammatory response. 
Increases in pro-inflammatory cytokines triggers the expression of 
endothelial adhesion molecules. The adhesion of neutrophils to the endothelium 
plays an important role in the inflammatory response. During inflammation, 
endothelial cell-leukocyte interactions are involved in tissue injury. Adhesion 
molecules are responsible for the interplay between cells of the endothelium and 
neutrophils resulting in their migration from the intravascular space to tissues (Yao, 
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Redl et al. 1998; Dayal, Hasko et al. 2002). These adhesion molecules include 
selectins and integrins (Yao, Redl et al. 1998; Dayal, Hasko et al. 2002; Tizard 
2004). Selectin-mediated binding is weak and transient (Tizard 2004); it initiates 
the interaction between leukocytes and the endothelium (Angle, Hoyt et al. 1997). 
Integrin-mediated binding is strong (Tizard 2004) and coordinates extravasation 
(Angle, Hoyt et al. 1997). The primary adhesion molecules on polymorphonuclear 
(PMN) cells are L-selectin and integrin subunits CD11a, CD11b, and CD18; on the 
endothelium, P-selectin and intercellular adhesion molecule-1 (ICAM-1) are the 
main adhesion molecules expressed (Yao, Redl et al. 1998; Dayal, Hasko et al. 
2002; Tizard 2004). Integrin expression on hemorrhaged-rat neutrophils from 
peripheral blood can be quantified using flow cytometry. Additionally, adhesion 
can be assessed in vitro in a quantitative endothelial cell-neutrophil adhesion assay 
(Barouch, Miyamoto et al. 2000). 
The effects of melatonin in the regulation of the solute content of the plasma 
should be investigated. Recently, melatonin has been suggested to have 
osmoregulatory effects in both terrestrial vertebrates and fish (Kulczykowska 
2001).  It has been suggested that melatonin can reduce glomerular filtration rate 
(GFR) (Tsuda, Ide et al. 1995) and urinary K+, Na+, and Cl- excretion (Koopman, 
Minors et al. 1989), increasing plasma osmolarity. It is possible that the 
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administration of BHB/M regulates plasma expansion not only through a 
physicochemical mechanism involving an osmolar gradients but also through 
physiological mechanisms involving renal function. 
Melatonin has also been implicated in circadian changes in blood pressure. 
In normal physiological function, blood pressure dips during sleep (Kryger, Roth 
et al. 2010). Melatonin production has been reported to be impaired in human 
patients with nocturnal hypertension. Non-dipping hypertensive individuals 
showed a reduction in nocturnal blood pressure after melatonin supplementation 
(Grossman, Laudon et al. 2006; Paulis and Simko 2007; Simko and Paulis 2007). 
Considering blood pressure is greatly reduced in hemorrhagic shock, it may seem 
paradoxical that the administration of melatonin would be beneficial to the bleeding 
individual. However, melatonin peaks during the dark phase of the day regardless 
of whether an animal is nocturnal or diurnal (Arendt 1995). It is possible that the 
nighttime effects of melatonin in diurnal mammals (e.g. humans) is opposite to 
those in nocturnal animals (e.g. rats). Perhaps a different rodent model of 
hemorrhagic shock is warranted in order to observe the effects of BHB/M in a 
diurnal mammal. The Sudanian grass rat (Arvicanthis ansorgei) has been used in 
numerous experiments comparing responses of nocturnal and diurnal rats 
(Dardente, Klosen et al. 2002; Dardente, Menet et al. 2004; Tournier, Dardente et 
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al. 2007) and could potentially offer a better rodent model of hemorrhagic shock, 
particularly when the objective is the development of therapies for human use. 
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Appendix I: Blood Volume Experiments 
Four different formulas were compared before deciding which one to use to 
calculate blood volume (ml): 1) 6% of total body weight (g), 2) 6.5 % of total body 
weight, 3) 7% of total body weight, and 4) 6% of total body weight plus 0.77 ml. 
Acute (no blood return) surgeries were conducted in which animals were bled to 
60% of their calculated blood volume based on the formulas above. Mean survival 
times in minutes were 740.50 ± 225.75, 6.50 ± 2.60, 0.75 ± 0.25, and 74.17 ± 49.30, 
respectively (Figure I.1). 
A 
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B 
 
Figure I.1. Blood Volume Calculation: Kaplan-Meier plot of animals subjected to 60% blood 
loss at (A) 10 minutes and (B) 1440 minutes (24 hours). 
Rats were hemorrhaged to 60% of their calculated blood volume in ml based on 6% of their total 
body weight (n=5), 6.5% of their total body weight (n=3), 7%of their total body weight (n=3), or 
6% of their total body weight plus 0.77 ml (n=6). . Times on the x-axis reflect minutes after 
achieving 60% blood loss. Some lines may be indistinguishable due to overlap. 
For our experiments, we decided to use the fourth formula, 6% of total body 
weight plus 0.77 ml, for numerous reasons. Firstly, when hemorrhaging animals to 
60% of their total blood volume calculated as 6% of the total body weight, the rats’ 
survival surpassed expectations. In fact, some individuals had to be censored after 
24 hours of monitoring. Considering these individuals did not have any 
resuscitative strategies applied to them, it would be difficult to assess the benefit of 
a resuscitation fluid and/or a blood transfusion since they seemed to be able to 
compensate for the hemorrhagic insult using only innate responses. However, when 
using 6.5% or 7% of the total body weight to calculate blood volume, the insult was 
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so great that the animals were dying too fast. Secondly, larger individuals have 
smaller blood volumes relative to their size than smaller animals. The 6% of total 
body weight plus 0.77 ml formula takes this into account. Finally, we found that 
when hemorrhaging rats to 40% of their calculated blood volume using this formula 
we consistently achieved a MAP of 25 mmHg (Figure I.2). 
 
Figure I.2. Blood Volume Calculation: Volume (ml) comparisons between the calculated blood 
volume using the 6% of total body weight (g) plus 0.77 ml formula and the blood withdrawn 
in order to obtain a MAP of 25 mmHg. 
The left column represents 40% of the calculated blood volume. The right column represents the 
volume recorded when animals reached a MAP of 25 mmHg (n=310). The line in the middle of the 
columns represents the mean. Error bars represent ranges. 
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Appendix II: Tissue Processing Protocol 
This protocol was ran in a Tissue-Tek VIP 1000 tissue processor (Model 4617. 
Miles Laboratories Inc. Naperville, IL). 
1. Bathe in 10% formalin for 30 minutes. 
2. Bathe in 50% ethanol for 45 minutes. 
3. Bathe in 70% ethanol for 45 minutes. 
4. Bathe in 95% ethanol for 45 minutes. 
5. Bathe in clean 95% ethanol for 45 minutes. 
6. Bathe in 100% ethanol for 45 minutes. 
7. Bathe in clean 100% ethanol for 45 minutes. 
8. Bathe in xylene for 45 minutes. 
9. Bathe in clean xylene for 60 minutes. 
10. Bathe in paraffin for 30 minutes. 
11. Bathe in clean paraffin for 30 minutes. 
12. Bathe in clean paraffin for 30 minutes. 
13. Bathe in clean paraffin for 30 minutes. 
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Appendix III: Hematoxylin and Eosin Staining Protocol 
This protocol was ran in an Autostainer XL (Australian Biomedical Corporation 
Ltd. Melbourne, Australia). 
1. Bake in the oven for 30 minutes. 
2. Dip in xylene for 5 minutes. 
3. Dip in xylene for 5 minutes. 
4. Dip in 100% ethanol for 2 minutes. 
5. Dip in 100% ethanol for 2 minutes. 
6. Dip in 70% ethanol for 2 minutes. 
7. Wash in running deionized water for 2 minutes. 
8. Dip in hematoxylin for 5 minutes. 
9. Wash in running deionized water for 2 minutes. 
10. Dip in 2% glacial acetic acid for 4 seconds. 
11. Wash in running deionized water for 2 minutes. 
12. Dip in 2% ammonia water for 10 seconds. 
13. Wash in running deionized water for 2 minutes. 
14. Dip in 95% ethanol for 1 minute. 
15. Dip in eosin for 1 minute. 
16. Dip in 95% ethanol for 1 minute. 
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17. Dip in 100% ethanol for 2 minutes. 
18. Dip in 100% ethanol for 2 minutes. 
19. Dip in xylene for 2 minutes. 
20. Dip in xylene for 2 minutes. 
  
1
2
3
4
5
6
7
W
A
S
H
 1
W
A
S
H
 2
W
A
S
H
 3
W
A
S
H
 4
W
A
S
H
 5
O
V
E
N
E
X
IT
1
8
1
7
1
6
1
5
1
4
1
3
1
2
1
1
1
0
9
8
L
O
A
D
E
o
s
in
9
5
%
 
E
tO
H
A
m
o
n
ia
 
W
a
te
r
X
y
le
n
e
X
y
le
n
e
1
0
0
%
 
E
tO
H
1
0
0
%
 
E
tO
H
9
5
%
 
E
tO
H
A
c
e
tic
 
A
c
id
X
y
le
n
e
X
y
le
n
e
1
0
0
%
 
E
tO
H
1
0
0
%
 
E
tO
H
7
0
%
 
E
tO
H
H
e
m
a
to
-
x
y
lin
 160 
 
Appendix IV: D-BHB Assay 
Absorbance values were read in a SpectraMax Plus384 plate reader (Molecular 
Devices, LLC. Sunnyvale, CA). 
Software Setup 
Wavelength    505 nm 
Temperature    37°C 
Mode     End Point 
Plate Setup 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Stnd01 
10.417 
mg/dL 
Stnd02 
5.209 
mg/dL 
Stnd03 
2.604 
mg/dL 
Stnd04 
0 
mg/dL 
Ctrl 
       
B  
Unknown 1 (in triplicate) 
  
       
C  
Unknown 2 (in triplicate) 
  
       
D  
Unknown 3 (in triplicate) 
  
       
E  
Etc… 
  
       
F             
G             
H             
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Procedure 
1. Place 107.5 µl of Enzyme R1 on all wells to be used 
2. Incubate for 3 minutes at 37°C 
3. Add standard, control, and sample volumes to respective wells. Follow volume 
guidelines: 
Standard 01  3 µL BHB Standard 
Standard 02 1.5 µL BHB Standard 
Standard 03 0.75 µL BHB Standard 
Standard 04  
Control 3 µL Distilled water 
Unknowns 3 µL Sample 
4. Immediately measure at 505nm (Read 1) 
5. Add 18 µL of Catalyst R2 
6. Wait 5 minutes 
7. Measure at 505 nm (Read 2) 
Calculation 
BHB (mM) = 
Read 2Unknown – Read 1Unknown 
Read 2Standard – Read 1Standard 
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Note: Large concentrations might need to be diluted with distilled water. If diluted, calculation should be adjusted by 
multiplying the results by the dilution factor used. 
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Appendix V: TNF-α Assay 
Absorbance values were read in a SpectraMax Plus384 plate reader (Molecular 
Devices, LLC. Sunnyvale, CA). 
Software Setup 
Wavelength    450 nm 
Temperature    Room 
Mode     End Point 
Plate Setup 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Stnd 001 
750 pg/ml 
Unknown 001 
        
B Stnd 002 
375 pg/ml 
Unknown 002 
        
C Stnd 003 
187.5 pg/ml 
Unknown 003 
        
D Stnd 004 
93.8 pg/ml 
Etc. 
        
E Stnd 005 
46.9 pg/ml 
  
        
F Stnd 006 
23.4 pg/ml 
          
G Stnd 007 
11.7 pg/ml 
          
H Stnd 008 
0 pg/ml 
          
 164 
 
Procedure 
1. Bring all solutions to room temperature. 
2. Create Standard Solutions. 
a. Fill one tube with 375 µL of Standard Diluent Buffer. 
b. Fill seven tubes with 300 µL of Standard Diluent Buffer. 
c. Create standard dilutions as explained in the diagram below. 
 
3. Prepare samples. 
a. Dilute 20 µL of sample in 40 µL of Standard Diluent Buffer 
b. Dilute 60 µL of the sample/standard diluent buffer solution in 180 µL of 
Incubation Buffer 
4. Add 100 µL of standard dilutions (From Step 2) to appropriate wells in 
duplicates. 
5. Add 100 µL of diluted samples (From Step 3) to appropriate wells in duplicates. 
6. Cover plate and incubate in the dark for 2 hours at room temperature. 
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7. While waiting, dilute Wash Buffer 1:24. Final volume depends on amount to 
be used. 
8. After the 2 hour wait, decant wells. 
9. Wash wells 4 times. 
a. Add 400 µL of Wash Buffer to all wells. 
b. Allow to soak for 15 to 30 seconds. 
c. Decant. 
d. Repeat 
10. Add 100 µL of Rt TNF-α Biotin Conjugate to all wells being used. 
11. Cover plate and incubate in the dark for 1 hour at room temperature. 
12. While waiting, make Streptavidin-HRP Working Solution. 
a. Dilute 120 µL of Streptavidin-HRP Concentrate in 12 mL of Streptavidin-HRP 
Diluent. 
13. After the 2 hour wait, decant wells. 
14. Wash wells 4 times (see Step 9). 
15. Add 100 µL of Streptavidin-HRP Working Solution to all wells being used. 
16. Cover plate and incubate in the dark for 30 min at room temperature. 
17. After the 30 min wait, decant wells. 
18. Wash wells 4 times (see Step 9). 
19. Add 100 µL of Stabilized Chromogen to all wells being used. 
20. Cover plate and incubate in the dark for 30 min at room temperature. 
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21. Add 100 µL of Stop Solution to all wells being used. 
22. Mix plate. 
23. Read absorbance at 450 nm. 
24. Generate standard curve 
25. Read concentrations from the standard curve. 
26. Multiply values obtained by 6 to correct for dilutions in Step 3. 
